

(19) World Intellectual Property Organization
International Bureau



173 #5
CEDA - 000126A



(43) International Publication Date
2 August 2001 (02.08.2001)

PCT

(10) International Publication Number
WO 01/54771 A2

- (51) International Patent Classification: A61P (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (21) International Application Number: PCT/US01/02743
- (22) International Filing Date: 26 January 2001 (26.01.2001)
- (25) Filing Language: English
- (26) Publication Language: English (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (30) Priority Data:
09/491,500 26 January 2000 (26.01.2000) US
09/615,854 14 July 2000 (14.07.2000) US
- (71) Applicant: CEDARS-SINAI MEDICAL CENTER [US/US]; 8700 Beverly Boulevard, Los Angeles, CA 90048-1865 (US).
- (72) Inventors: BLACK, Keith, L.; 1233 Roberto Lane, Los Angeles, CA 90077 (US). NINGARAJ, Nagendra, S.; 6024 Buckingham Parkway #5, Culver City, CA 90230 (US).
- Published:**
— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD FOR USING POTASSIUM CHANNEL AGONISTS FOR DELIVERING A MEDICANT TO AN ABNORMAL BRAIN REGION AND/OR A MALIGNANT TUMOR

(57) Abstract: Disclosed are methods of selectively delivering a medicant to an abnormal brain region and/or to a malignant tumor in a mammalian subject, including a human. A medicant is administered simultaneously or substantially simultaneously with a calcium- or ATP-dependent potassium channel [K_{Ca} or K_{ATP}] activator (other than bradykinin or a bradykinin analog), such as a direct potassium channel agonist or an indirect potassium channel activator, such as an activator of soluble guanylyl cyclase (e.g., nitric oxide or a nitric oxide donor) or an activator of cyclic GMP-dependent protein kinase, whereby the medicant is delivered selectively to the cells of the abnormal brain region and/or to the tumor, compared to normal tissues. Thus, among the disclosures is a method of treating a malignant tumor in a human subject. Also disclosed are pharmaceutical compositions that combine a potassium channel activator together with a medicant and a kit for enhancing the delivery of a medicant to an abnormal brain region and/or to a malignant tumor.

METHOD FOR USING POTASSIUM CHANNEL AGONISTS
FOR DELIVERING A MEDICANT TO AN ABNORMAL BRAIN REGION
AND/OR A MALIGNANT TUMOR

5

BACKGROUND OF THE INVENTION

Throughout the application various publications are referenced in parentheses. The disclosures of these publications in their entireties are hereby incorporated by reference in the application in order to more fully describe the state of the art to which this invention pertains.

10

1. THE FIELD OF THE INVENTION

This invention relates to the medical arts. In particular, it relates to a method of enhancing the delivery of a medicant across abnormal microvasculature to a tissue requiring treatment.

15

2. DISCUSSION OF THE RELATED ART

Pathologic neovascularization, i.e., the proliferation or development of new blood vessels, is essential for the growth and spread of primary, secondary and metastatic malignant tumors. It is known that certain properties of the new capillaries and arterioles constituting the neomicrovasculature in solid tumors differ from those of normal microvasculature. (J. Denekamp *et al.*, *Vasculature and microenvironmental gradients: the missing links in novel approaches to cancer therapy?*, Adv. Enzyme Regul. 38:281-99 [1998]). Neomicrovasculature induced by angiogenic factors from malignant cells was reported to possess altered pharmacological reactivity to some vasoconstricting agents, compared with neomicrovasculature that was not induced by neoplastic cells. (S.P. Andrade and W.T. Beraldo, *Pharmacological reactivity of neoplastic and non-neoplastic associated neovasculature to vasoconstrictors*, Int. J. Exp. Pathol. 79(6):425-32 [1998]).

20

25

A number of proposed cancer treatments have been based on differences between neomicrovasculature and normal microvasculature. For example, combretastatin A-4 was shown to cause vascular damage and occlusion selectively in the blood vessels of malignant tumors compared to normal blood vessels. (G.G. Dark *et al.*, *Combretastatin A-4, an agent*

30

that displays potent and selective toxicity toward tumor vasculature, *Cancer Res.* 57(10):1829-34 [1997]; D.J. Chaplin *et al.*, *Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate*, *Anticancer Res.* 19(1A):189-95 [1999]). Monoclonal antibodies have been directed to antigens and antigenic combinations specific to endothelial cells of pathologic neovasculature, such as vascular cell adhesion molecule (VCAM)-1, phosphatidylserine (PS), the glycoprotein endosialin, and prostate-specific membrane antigen (PSMA), with the aim of selectively inducing thrombosis in neovasculature. (E.g., S. Ran *et al.*, *Infarction of solid Hodgkins tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature*, *Cancer Res.* 58(20):4646-53 [1998]; I. Ohizumi *et al.*, *Antibody-based therapy targeting tumor vascular endothelial cells suppresses solid tumor growth in rats*, *Biochem. Biophys. Res. Commun.* 236(2):493-96 [1997]; S.S. Chang *et al.*, *Five different antiprostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature*, *Cancer Res.* 59(13):3192-98 [1999]; W.J. Rettig *et al.*, *Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer*, *Proc. Natl. Acad. Sci. USA* 89(22):10832-36 [1992]). But taken alone, shutting down blood flow through the neomicrovasculature to malignant tumors may not necessarily result in stopping tumor growth, because actively proliferating populations of neoplastic cells at the periphery of solid tumors may have access to blood supplied by normal microvasculature. (E.g., D.J. Chaplin *et al.* [1999]).

Consequently, other conventional and novel therapeutic modalities will continue to be of value in the treatment of malignant, solid tumors. However, the efficacy of novel therapeutic agents, including cytotoxic chemotherapeutic agents, monoclonal antibodies, cytokines, effector cells, and viral particles has been limited by their ability to reach their targets in vivo in adequate quantities. (E.g., R.K Jain, *Vascular and interstitial barriers to delivery of therapeutic agents in tumors*, *Cancer Metastasis Rev.* 9(3):253-66 [1990]). An important limiting factor is the low permeability to macromolecules and viral particles of neomicrovasculature supplying the tumors.

This problem of microvascular permeability is especially acute with respect to malignant tumors of the central nervous system. These malignancies are usually fatal, despite recent advances in the areas of neurosurgical techniques, chemotherapy and radiotherapy. In particular, there are no standard therapeutic modalities that can substantially alter the prognosis

for patients with malignant tumors of the brain, cranium, and spinal cord. For example, high mortality rates persist for patients diagnosed with malignant medulloblastomas, malignant meningiomas, malignant neurofibrosarcomas and malignant gliomas, which are characterized by infiltrative tumor cells throughout the brain. Although intracranial tumor masses can be debulked surgically, treated with palliative radiation therapy and chemotherapy, the survival associated with intracranial tumors, for example, a glioblastoma, is typically measured in months. The development of new therapeutic modalities against solid brain tumors largely depends on transvascular delivery of the potential therapeutic agent.

Transvascular delivery of chemotherapeutic agents and viral particles to tumor cells or other abnormal brain tissue is hampered by the blood-brain barrier, particularly the blood-tumor barrier found in brain tumors. The blood-brain barrier is a transvascular permeability barrier thought to result from the interendothelial tight junctions formed by the cerebrovascular endothelial cells of brain capillaries and arterioles in both normal and abnormal brain tissue; the maintenance of the blood-brain barrier possibly involves endogenous nitric oxide production and a cyclic GMP-dependent mechanism. (Liu, S.M. and Sundqvist, T., *Nitric oxide and cGMP regulate endothelial permeability and F-actin distribution in hydrogen peroxide-treated endothelial cells*, Exp. Cell. Res. 235(1):238-44 [1997]). The blood-brain barrier protects the brain from changes in the composition of the systemic blood supply (e.g., in electrolytes) or from blood-borne macromolecules, such as immunoglobulins or other polypeptides, and prevents the transvascular delivery of many exogenously supplied pharmaceutical agents to brain tissues.

The treatment of brain tissue abnormalities, such as tumors, often involves the use of pharmaceutical agents with a significant toxicity of their own, making it highly desirable to be able to preferentially direct such agents to the abnormal or malignant tissue. While, there has been a great deal of interest in developing techniques which are capable of opening the blood-brain barrier to allow transport of pharmaceutical agents to the brain. Few of these methods are capable of selectively opening the blood-brain barrier only in the abnormal brain tissue while leaving the blood-brain barrier in the normal brain tissue intact.

For example, Neuwelt *et al.* used an intracarotid injection of hypertonic mannitol to osmotically disrupt the blood-brain barrier. They reported that this enhanced the uptake by brain tissue of inactivated HSV-1 particles that were administered immediately afterward by

intracarotid bolus injection. (E.A. Neuwelt *et al.*, *Delivery of ultraviolet-inactivated 35S-herpesvirus across an osmotically modified blood-brain barrier*, J. Neurosurg. 74(3):475-79 [1991]; Also, S.E. Doran *et al.*, *Gene expression from recombinant viral vectors in the central nervous system after blood-brain barrier disruption*, Neurosurgery 36(5):965-70 [1995]; G. Nilaver *et al.*, *Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption*, Proc. Natl. Acad. Sci. USA 92(21):9829-33 [1995]).

Intracarotid infusion of leukotriene C.sub.4 (LTC.sub.4) selectively increases the permeability in brain tumor capillaries without affecting the permeability in normal brain capillaries. The effect of LTC.sub.4 on brain tumor capillaries is, however, limited to small molecules and it can only slightly increase the permeability of those small molecules in abnormal brain tissue relative to normal. Accordingly, LTC.sub.4 does not significantly increase the delivery of some larger water soluble molecules to brain tumors or other abnormalities.

The vasoactive nanopeptide bradykinin and agonists or polypeptide analogs thereof (e.g., receptor-mediated permeabilizers [RMPs]) have been injected intravenously to increase blood-brain barrier permeability to co-administered neuropharmaceutical or diagnostic agents. (B. Malfroy-Camine, *Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability*, U.S. Patent No. 5,112,596; J.W. Kozarich *et al.*, *Increasing blood brain barrier permeability with permeabilizer peptides*, U.S. Patent No. 5,268,164). Intracarotid infusion of bradykinin will selectively increase permeability 2- to 12-fold in brain tumor and ischemic brain capillaries for molecules ranging in molecular weight from 100 to 70,000 Daltons (Inamura, T. *et al.*, *Bradykinin selectively opens blood-tumor barrier in experimental brain tumors*, J. Cereb. Blood Flow Metab. 14(5):862-70 [1994]). Bradykinin does not increase permeability in the normal blood brain barrier except at very high doses. (Wirth, K. *et al.*, *DesArg9-D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin (desArg10-[Hoe140]) is a potent bradykinin B1 receptor antagonist*, Eur. J. Pharmacol. 205(2):217-18 [1991]). Opening of the blood-tumor barrier by bradykinin is transient, lasting 15 to 20 minutes. (Inamura *et al.* [1994]). After opening of abnormal brain capillaries with bradykinin, the capillaries become refractory to the bradykinin effect for up to 60 minutes. (Inamura *et al.* [1994]).

A method for selectively delivering to abnormal brain tissue a neuropharmaceutical agent (e.g., 5-fluorouracil, cisplatin, methotrexate, or monoclonal antibodies) or a diagnostic agent (e.g., technicium-99 glucoheptonate, gallium-EDTA, and ferrous magnetic or iodinated contrasting agents) employed intracarotid infusion of bradykinin, or a bradykinin analog, such as RMP-7; the bradykinin or bradykinin analog was administered approximately contemporaneously with the agent. (K.L. Black, *Method for selective opening of abnormal brain tissue capillaries*, U.S. Patent Nos. 5,527,778 and 5,434,137). Enhanced transvascular delivery of HSV-derived viral particles to malignant cells in the brains of rats was also achieved by disrupting the blood-brain barrier with bradykinin or RMP-7. (N.G. Rainov, *Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms*, Hum. Gene Ther. 6(12):1543-52 [1995]; N.G. Rainov *et al.*, *Long-term survival in a rodent brain tumor model by bradykinin-enhanced intra-arterial delivery of a therapeutic herpes simplex virus vector*, Cancer Gene Ther. 5(3):158-62 [1998]; F.H. Barnett *et al.*, *Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7*, Cancer Gene Ther. 6(1):14-20 [1999]).

The calcium-activated potassium channel (K_{Ca}) is an important regulator of blood vessel tone (Nelson MT, Quayle JM. Physiological roles and properties of potassium channels in arterial smooth muscle, Am. J. Physiol. 268(4 Pt 1): C799-822[1995]; Bang, L. *et al.*, *Nitroglycerin-mediated vasorelaxation is modulated by endothelial calcium-activated potassium channels*, Cardiovasc. Res. 43(3):772-78 [1999]). The K_{Ca} channel is ubiquitously distributed in tissues as α and β subunits. Its activity is triggered by depolarization and enhanced by an increase in cytosolic calcium di-cation (Ca^{2+}). A local increase in Ca^{2+} is sensed by the extremely sensitive β -subunit of the K_{Ca} , directed towards the cytoplasm in the cell, that allows a significant potassium cation flux through these channels. Under conditions when intracellular cyclic 3', 5' adenosine monophosphate (cAMP) concentration rises in vascular endothelium (e.g. hypoxia), ATP-sensitive potassium channels (K_{ATP}) may also play a role. (J.E. Brian *et al.*, *Recent insights into the regulation of cerebral circulation*, Clin. Exp. Pharmacol. Physiol. 23(6-7):449-57 [1996]). Minoxidil sulfate and chromakalim are reported to be activators of K_{ATP} . (A.D. Wickenden *et al.*, *Comparison of the effects of the*

K(+)-channel openers cromakalim and minoxidil sulphate on vascular smooth muscle, Br. J. Pharmacol, 103(1):1148-52 [1991]).

Intimately connected with the regulation of potassium channels is guanosine 3',5'-cyclic monophosphate, commonly known as cyclic GMP (cGMP), an important signal transducing molecule, which mediates the regulation of three main classes of effector proteins: (1) cGMP-dependent protein kinases, which mediate protein phosphorylation; (2) cGMP-gated ion channel protein kinases, which mediate cation influx across the plasma membrane; and (3) phosphodiesterases, which mediate cyclic nucleotide catabolism. (Lohse, M.J. *et al.*, *Pharmacology of NO:cGMP signal transduction*, Naunyn-Schmiedebergs Arch. Pharmacol. 358:111-12 [1998]; Smolenski, A. *et al.*, *Functional analysis of cGMP-dependent protein kinases I and II as mediators of NO/cGMP effects*, Naunyn-Schmiedebergs Arch. Pharmacol. 358:134-39 [1998]; He, P. *et al.*, *cGMP modulates basal and activated microvessel permeability independently of $[Ca^{2+}]_i$* , Am. J. Physiol. 274(6 Pt 2):H1865-74 [1998]; Holschermann, H. *et al.*, *Dual role of cGMP in modulation of macromolecule permeability of aortic endothelial cells*, Am. J. Physiol. 272(1 Pt 2):H91-98 [1997]).

The production of cGMP from GTP is catalyzed by soluble guanylyl cyclase, a nitric oxide-activated enzyme. (Patel, A.I. and Diamond, J., *Activation of guanosine 3',5'-cyclic monophosphate (cGMP)-dependent protein kinase in rabbit aorta by nitroglycerin and sodium nitroprusside*, J. Pharmacol. Exp. Ther. 283(2):885-93 [1997]; Patel, A.I. *et al.*, *Activation of guanosine 3',5'-cyclic monophosphate (cGMP)-dependent protein kinase in rat vas deferens and distal colon is not accompanied by inhibition of contraction*, J. Pharmacol. Exp. Ther. 283(2):894-900 [1997]).

There is also evidence that nitric oxide participates in the regulation of microvascular tone. (Joo, F. *et al.*, *Regulation of the macromolecular transport in the brain microvessels: the role of cyclic GMP*, Brain Res. 278(1-2):165-74 1983)). For example, glial tumors and ischemic tissue are more immunopositive for nNOS and eNOS relative to normal brain. (Cai, Z. *et al.*, *Prenatal hypoxia-ischemia alters expression and activity of nitric oxide synthase in young rat brain and causes learning deficits*, Brain Res. Bull. 49(5):359-65 [1999]; Nakano, S. *et al.*, *Increased brain tumor microvessel permeability after intracarotid bradykinin infusion is mediated by nitric oxide*, Cancer Research, 56:4027-4031 [1996]; Faraci, F.M. *et al.*, *Role*

of soluble guanylate cyclase in dilator responses of the cerebral microcirculation, *Brain Res.* 821(2):368-73 [1999]). Further, the pretreatment of glioma-bearing rats with the NOS inhibitor, L-NAME, significantly reduces bradykinin-induced permeability. (Moncada, S. *et al.*, *Endogenous nitric oxide: physiology, pathology and clinical relevance*, *Eur. J. Clin. Invest.* 21(4):361-74 [1991]; Sugita, M. *et al.*, *Nitric oxide and cyclic GMP attenuate sensitivity of the tumor barrier to bradykinin*, *Neurological Research* 20: 559-563 [1998]).

In turn, one class of enzymes that is activated by cGMP (and cAMP) is cGMP-dependent protein kinases (PKG or cGK), which through enzymatic ATP-dependent phosphorylation, directly or indirectly activate calcium-dependent potassium channels (Robertson, B.E. *et al.*, *cGMP-dependent protein kinase activates Ca-activated K channels in cerebral artery smooth muscle cells*, *Am. J. Physiol.* 265[Cell Physiol. 34]:C299-C303 [1993]; Fukao, M. *et al.*, *Cyclic GMP-dependent protein kinase activates cloned BK_{Ca} channels expressed in mammalian cells by direct phosphorylation at serine 1072*, *J. Biol. Chem.* 274(16):10927-35 [1999]; Becker, E.M. *et al.*, *The vasodilator-stimulated phosphoprotein (VASP): target of YC-1 and nitric oxide effects in human and rat platelets*, *J. Cardiovasc. Pharmacol.* 35(3):390-97 [2000]). There is also evidence that nitric oxide can activate K_{Ca} by both cGMP-dependent and cGMP-independent mechanisms. (Chen, C.H. *et al.*, *Nitric oxide activates Ca²⁺-activated K⁺ channels in cultured bovine adrenal chromaffin cells*, *Neurosci. Lett.* 248(2):127-29 [1998]; Vaali, K. *et al.*, *Relaxing effects of NO donors on guinea pig trachea in vitro are mediated by calcium-sensitive potassium channels*, *J. Pharmacol. Exp. Ther.* 286(1):110-14 [1998]; Sobey, C.G. and Faraci, F.M., *Inhibitory effect of 4-aminopyridine on responses of the basilar artery to nitric oxide*, *Br. J. Pharmacol.* 126(6):1437-43 [1999]; Kurtz, A. *et al.*, *Mode of nitric oxide action on the renal vasculature*, *Acta Physiol. Scand.* 168(1):41-45 [2000]).

Treatments directed to the use of potassium channel activators or agonists have been taught for disorders including hypertension, cardiac and cerebral ischemia, nicotine addiction, bronchial constriction, and neurodegenerative diseases, but not particularly for the treatment of malignant tumors. (Erhardt *et al.*, *Potassium channel activators/openers*, U.S. Patent No. 5,416,097; Schohe-Loop *et al.*, *4, 4'-bridged bis-2, 4-diaminoquinazolines*, U.S. Patent No. 5,760,230; Sit *et al.*, *4-aryl-3-hydroxyquinolin-2-one derivatives as ion channel modulators*, U.S. Patent No. 5,922,735; Garcia *et al.*, *Biologically active compounds*, U.S.

Patent No. 5,399,587; Cherksey, *Potassium channel activating compounds and methods of use thereof*, U.S. Patent No. 5,234,947).

Bradykinin is thought to increase $[Ca^{2+}]_i$ and thus may activate K_{Ca} channels. While some other known activators of K_{Ca} do not act as vasodilators, for example, 1,3-dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-2H-benzimidazol-2-one (NS-1619; M. Holland *et al.*, *Effects of the BK_{Ca} channel activator, NS1619, on rat cerebral artery smooth muscle*, Br. J. Pharmacol., 117(1):119-29 [1996]), evidence is accumulating that K_{Ca} may play an important role in vasodilatation mediated by vasodilators, such as bradykinin, nitric oxide donors, cyclic guanosine monophosphate (cGMP), and guanylyl cyclase activators. (Berg T., Koteng O., *Signaling pathways in bradykinin- and nitric oxide-induced hypotension in the normotensive rat; role of K^+ -channels*, Br. J. Pharmacol.;121(6):1113-20 [1997]; Bolotina, V.M. *et al.*, *Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle*, Nature 368(6474):850-3 [1994]; Robertson, B.E., *et al.*, *cGMP-dependent protein kinase activates Ca-activated K channels in cerebral artery smooth muscle cells*, Am. J. Physiol. 265(1 Pt 1):C299-303 [1993]; Sobey, C.G. *et al.*, *Mechanisms of bradykinin-induced cerebral vasodilatation in rats. Evidence that reactive oxygen species activate K^+ channels*, Stroke 28(11):2290-4; discussion 2295 [1997]; C.G. Sobey and F.M. Faraci, *Effect of nitric oxide and potassium channel agonists and inhibitors on basilar artery diameter*, Am. J. Physiol. 272(1 Pt 2):H256-62 [1997]; Hardy, P. *et al.*, *A major role for prostacyclin in nitric oxide-induced ocular vasorelaxation in the piglet*, Circ. Res. 83(7):721-29 [1998]; Bychkov R. *et al.*, *Calcium-activated potassium channels and nitrate-induced vasodilation in human coronary arteries*, J. Pharmacol. Exp. Ther. 285(1):293-98 [1998]; Armstead, W.M., *Contribution of K_{Ca} Channel activation to hypoxic cerebrovasodilation does not involve NO*, Brain Res. 799(1):44-48 [1998]).

Bradykinins action as a powerful vasodilator is disadvantageous when using bradykinin to open the blood-brain barrier to therapeutic anticancer agents. Bradykinin or its analogs may adversely lower blood pressure, reduce cerebral blood flow, or contribute to brain edema in some patients. (E.g., A.M. Butt, *Effect of inflammatory agents on electrical resistance across the blood-brain barrier in pial microvessels of anesthetized rats*, Brain Res. 696(1-2):145-50 [1995]). In addition, bradykinin constricts smooth muscle and stimulates pain receptors.

Consequently, there is still a definite need to maximize the effectiveness of a wide variety of therapeutic agents through enhanced selective transvascular delivery to malignant tumors, including those of the central nervous system, and/or to other abnormal brain regions. These and other benefits the present invention provides as described herein.

SUMMARY OF THE INVENTION

The present invention relates to a method of delivering a medicant to an abnormal brain region in a mammalian subject, including a human. The method includes administering to the subject a potassium channel activator (i.e., activator of calcium- or ATP-dependent potassium channels [K_{Ca} or K_{ATP}]). Potassium channel activators include direct agonists (other than bradykinin or bradykinin analogs), such as NS-1619 or minoxidil. Potassium channel activators also include compounds that indirectly activate potassium channels, for example nitric oxide, nitric oxide donors, and other activators of guanylyl cyclase. Activators of cyclic GMP-dependent protein kinase, which activates calcium-dependent potassium channels, are also included. The potassium channel activator is administered to the subject under conditions and in an amount sufficient to increase the permeability to the medicant of a capillary or arteriole delivering blood to cells of the abnormal brain region in the subject. Simultaneously or substantially simultaneously with the potassium channel activator, the medicant is administered, so that the medicant is delivered selectively to the cells of the abnormal region compared to normal brain regions, due to the increased permeability of capillaries and arterioles supplying the abnormal brain region. The method is particularly valuable in the treatment of physical or biochemical brain injuries caused by trauma, infection, stroke, ischemia, and, particularly, malignant brain tumors, for which survival rates are notoriously poor.

The present invention also relates to a method of delivering a medicant to a malignant tumor in the brain or anywhere in the body of a mammalian subject. The method involves administering to the subject a potassium channel activator, such as a potassium channel agonist other than bradykinin or a bradykinin analog, under conditions and in an amount sufficient to increase the permeability to the medicant of a capillary or arteriole delivering blood to cells of the malignant tumor in the subject. Simultaneously or substantially simultaneously with the potassium channel activator the medicant is administered to the subject, and it is delivered

selectively to the malignant cells compared to non-malignant cells by virtue of the potassium channel activator. The inventive method is useful in treating any kind of malignant tumor by increasing the selectivity of drug delivery to neoplastic tissue, thereby minimizing damage to non-malignant tissue from medicants, including cytotoxic chemotherapeutic agents, and focusing the therapeutic or diagnostic action of the agents. Thus, this invention, also directed to a method of treating a malignant tumor in a human subject, offers enhanced prospects of survival to cancer patients, with fewer harmful side effects. The selectivity of the methods is based on the role of calcium- and ATP-dependent potassium transporters (channels) in mediating the permeability of microvasculature to various drugs, macromolecules, and viral particles, combined with the greater number of calcium- and ATP-dependent potassium channels present in abnormal brain vasculature or tumor neomicrovasculature compared to normal microvasculature.

The present invention also relates to a pharmaceutical composition that comprises a combination of a potassium channel activator, other than bradykinin or a bradykinin analog, formulated in a pharmaceutically acceptable solution together with a medicant for delivery by intravascular infusion or bolus injection into a mammal, such as a human. The pharmaceutical composition is useful in practicing the inventive methods.

The invention also relates to a kit for enhancing the delivery of a medicant to an abnormal brain region and/or to a malignant tumor.

These and other advantages and features of the present invention will be described more fully in a detailed description of the preferred embodiments which follows.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the response to the soluble guanylyl cyclase activator YC-1 ($2.66 \mu\text{g min}^{-1} \text{ kg}^{-1}$; $n = 6$) in the unidirectional transfer constant K_i for [^{14}C] α -aminoisobutyric acid in malignant RG2 glioma tissue in Wistar rats, compared to DMSO + saline control ($n = 6$), YC-1 + iberiotoxin (IBTX; $0.2 \mu\text{g IBTX min}^{-1} \text{ kg}^{-1}$; $n = 3$), or YC-1 + a selective inhibitor of soluble guanylyl cyclase, 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) ($2.66 \mu\text{g min}^{-1} \text{ kg}^{-1}$; $n = 4$) treatments for 15 minutes each. K_i ($\mu\text{L/g/min}$) in the tumor core (gray bars), tumor-adjacent

tissue taken about 3 mm from the tumor core (white bars), and normal contralateral brain tissue (black bars) is shown.

Figure 2 shows the enhancing effect of the nitric oxide donor diethylamine-*NONO*ate (DEA/NO) on blood-tumor barrier permeability to Evans blue stain in malignant RG2 glioma tissue in Wistar rats. Figure 2A shows a brain section from a rat treated with phosphate buffered saline (PBS only control). Figure 2B shows a brain section from a DEA/NO-treated rat.

Figure 3 shows the response to DEA/NO ($2.66 \mu\text{g min}^{-1} \text{kg}^{-1}$; $n = 3$) in the unidirectional transfer constant K_i for [^{14}C] α -aminoisobutyric acid in malignant RG2 glioma tissue in Wistar rats, compared to PBS control, DEA/NO + iberiotoxin (IBTX; $0.2 \mu\text{g IBTX min}^{-1} \text{kg}^{-1}$; $n = 3$), or PAPA/NO ($2.66 \mu\text{g min}^{-1} \text{kg}^{-1}$; $n = 3$) treatments for 15 minutes each. K_i ($\mu\text{L/g/min.}$) in tumor centers (black bars), tumor-adjacent tissue taken about 3 mm from the tumor core (white bars), and normal contralateral brain tissue (cross-hatched bars) is shown.

Figure 4 shows transendothelial vesicular transport in a RG2 tumor capillary. RG2 tumor-bearing brain sections from Wistar rats were prepared after a 15-minute intracarotid infusion with: PBS (0.8 mL)(Figure 4A; 54,000x magnification); bradykinin ($10 \mu\text{g min}^{-1} \text{kg}^{-1}$)(Figure 4B; 87,000x magnification); or NS-1619 ($5.3 \mu\text{g min}^{-1} \text{kg}^{-1}$; Figure 4C; 87,000x magnification). TEM analysis of the tumor center section shows that K_{Ca} activators bradykinin and NS-1619 increase pinocytotic transport vesicles in the endothelial cytoplasm.

Figure 5 shows that a potassium channel activator (bradykinin) increases transport of horse radish peroxidase (HRP) from the tumor capillary lumen through endothelial pinocytotic vesicles. Figure 5A (8,700x magnification) and Figure 5B (21,000x magnification) show vascular and tumor tissue from a rat in the PBS control group. Figure 5C (8,700x magnification) and Figure 5D (21,000x magnification) show vascular and tumor tissue from a rat treated with the potassium channel activator bradykinin.

Figure 6 illustrates that a potassium channel activator (bradykinin) induces vesicular transport of HRP in RG2 tumor cells. Figure 6A (8,700x magnification) shows tumor tissue from a rat in the PBS control; Figure 6B (10,800x magnification) and Figure 6C (21,000x magnification) show tumor tissue from a bradykinin-treated rat.

Figure 7 shows an increase in the unidirectional transport constant caused by the K_{ATP} activator minoxidil sulfate and the K_{Ca} activator bradykinin.

Figure 8 shows that bradykinin-induced increase in K_i was not attenuated by glibenclamide, while IBTX significantly decreased the effect caused by bradykinin.

Figure 9 shows that the minoxidil sulfate-induced increase in K_i was attenuated by glibenclamide, while IBTX failed to block the effect.

5 Figure 10 illustrates increased microvascular permeability in an ischemic brain region as a result of treatment with a potassium channel activator. K_i is shown for bradykinin-treated (black bars) and control animals (gray bars) in paired histograms; tissues tested were (left to right): caudate putamen; cortex; caudate putamen contralateral side; and cortex contralateral side. Figure 10A shows that blood-brain barrier permeability after one hour of ischemia was not
10 affected by bradykinin treatment compared to the vehicle-treated group (MCA occlusion for 1 hour, followed by 1 hour of reperfusion; Inset: autoradiograph). Figure 10B shows that bradykinin significantly increased permeability in ischemic infarct penumbra after 2 hours of MCA occlusion, followed by 1 hour of reperfusion (Inset: autoradiograph).

Figure 11 shows that potassium activators enhance permeability of microvasculature in
15 ischemic brain tissue. No change in blood-brain barrier permeability at the infarct brain tissue (significantly less uptake of Evans blue) was observed in a rat subjected to temporary ischemia (2 hours MCA occlusion and 1 hour of reperfusion; top and bottom left panels). Considerable enhancement of Evans blue uptake was seen in ischemic brain tissue in bradykinin-treated ($10 \mu\text{g min}^{-1}\text{kg}^{-1}$ for 15 min; top middle panel) or NS-1619-treated ($1.5 \mu\text{g min}^{-1}\text{kg}^{-1}$ for 15 min;
20 lower middle panel) rats compared to PBS vehicle-treated (top and bottom left panels). However, co-infusion with IBTX ($0.2 \mu\text{g min}^{-1}\text{kg}^{-1}$ for 15 min) attenuated the increased uptake of Evans blue induced by bradykinin (top right panel) or NS-1619 (bottom right panel).

Figure 12A shows the enhancing effect of NS-1619 on blood-tumor barrier permeability to [^{14}C] -aminoisobutyric acid (AIB) tracer (left) compared to the effect on
25 blood-brain barrier permeability in normal brain tissue adjacent (middle) and contralateral (right) to malignant RG2 glioma tissue in Wistar rats.

Figure 12B shows the enhancing effect of minoxidil sulfate on blood-tumor barrier permeability to [^{14}C]AIB tracer (left) compared to the effect on blood-brain barrier permeability
30 in normal brain tissue adjacent (middle) and contralateral (right) to malignant RG2 glioma tissue in Wistar rats.

Figure 13 shows a dose-response to NS-1619 in the unidirectional transfer constant K_i for [^{14}C] -aminoisobutyric acid in malignant RG2 glioma tissue in Wistar rats. $K_i = \text{L/g/min}$.

Figure 14 shows specific inhibition by iberiotoxin (IBTX; $2.3 \mu\text{g kg}^{-1} \text{min}^{-1}$) of the permeability increasing effect of NS-1619 ($26.5 \mu\text{g kg}^{-1} \text{min}^{-1}$). The K_i was determined in RG2 tumor-bearing Wistar rats using [^{14}C]AIB with NS-1619 ($26.5 \mu\text{g kg}^{-1} \text{min}^{-1}$) with or without IBTX ($2.3 \mu\text{g kg}^{-1} \text{min}^{-1}$), for 15 minutes. The results are compared with PBS, pH 7.4 with or without 5% ethanol.

Figure 15 shows intense over-expression of K_{Ca} as indicated by anti- K_{Ca} immunostain of glioma tissue (Fig. 15B), compared to normal contralateral brain tissue (Fig. 15A). Magnification is 100x.

Figure 16 shows intense over-expression of K_{ATP} as indicated by anti- K_{ATP} (anti-Kir 6.2) immunostain of RG2 (Fig. 16C) or C6 (Fig. 16D) glioma tissue from tumor centers, compared to normal brain tissue (Fig. 16A) and RG2 tumor periphery (Fig. 16B). Magnification is 100x.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The inventive methods are useful for selectively delivering a medicant to abnormal brain regions and/or malignant tumors in mammalian subjects. The methods involve administering to the mammalian subject a potassium channel activator, other than bradykinin or a bradykinin analog, under conditions and in an amount sufficient to increase the permeability to the medicant of a capillary or arteriole delivering blood to cells of the abnormal brain region and/or to malignant cells of a malignant tumor present in the subject. The increase in permeability ranges from at least 2-to 6-fold, compared to controls without the administration of a potassium channel activator. The relative increase in permeability tends to be greater for large molecular weight medicants (e.g., about 10,000 to 250,000 Daltons) than for smaller molecular weight substances (e.g., about 50-200 Daltons).

The abnormal brain regions include regions of brain tissue physiologically directly affected by a physical or biochemical injury, for example, Alzheimers disease, Parkinsonism, trauma, infection, stroke, brain ischemia, or regions of neoplastic growth within the brain, such as benign or malignant brain tumor tissues.

The present invention is also useful for selectively delivering a medicant to a malignant tumor in the brain or to a tumor elsewhere in the body of a mammalian subject. The inventive technology is useful in the treatment of all kinds of solid malignant tumors, including gliomas, glioblastomas, oligodendrogliomas, astrocytomas, ependymomas, primitive neuroectodermal tumors, atypical meningiomas, malignant meningiomas, neuroblastomas, sarcomas, melanomas, lymphomas, or carcinomas. The tumor to be treated can be contained in the skull, brain, spine, thorax, lung, peritoneum, prostate, ovary, uterus, breast, stomach, liver, bowel, colon, rectum, bone, lymphatic system, skin, or in any other organ or tissue of the subject.

The inventive methods are useful in treating any mammal, including a human, non-human primate, canine, feline, bovine, porcine or ovine mammal, as well as in a small mammal such as a mouse, rat, gerbil, hamster, or rabbit.

The potassium channel activator is an activator of either a calcium-activated potassium channel (K_{Ca}) of any conductance level, whether of large, intermediate, or small conductance, or of an ATP-sensitive potassium channel (K_{ATP}). Included are direct agonists of K_{Ca} , such as 1,3-dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-2H-benzimidazol-2-one (NS-1619) or 1-ethyl-2-benzimidazolinone (1-EBIO).

Also included among useful potassium channel activators are compounds that indirectly activate potassium channels, for example activators of soluble guanylyl (i.e., guanylate) cyclase, such as nitric oxide, nitric oxide donors, metalloporphyrins (e.g., zinc or tin protoporphyrin IX), YC-1 (a benzyl indazole derivative), or guanylyl cyclase activating proteins (GCAPs). (See, e.g., Koesling, D., *Modulators of soluble guanylyl cyclase*, Naunyn-Schmiedeberg's Arch. Pharmacol. 358:123-126 [1998]).

Examples of useful potassium channel activators that are K_{ATP} agonists include minoxidil (2,4-diamino-6-piperidino pyrimidine-3-oxide; insoluble in water, soluble in ethanol 29 mg/mL), pinacidil ((+/-)-N-cyano-N'-4-pyridinyl-N'-(1,2,2-trimethyl propyl)-guanidine; insoluble in water, soluble in ethanol 14 mg/mL), (+)-cromakalim, (-)-cromakalim or levromakalim, (+/-)-cromakalim, or diazoxide.

A preferred potassium channel activator is nitric oxide gas, which is fully permeable across biological membranes. Inhalable nitric oxide gas can be administered to the subject by mask in a controlled gas mixture as is known in the art. (E.g., Kieler-Jensen, N. *et al.*, *Inhaled*

nitric oxide in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance, J Heart Lung Transplant. 13(3):366-75 [1994]; Rajek, A. *et al.*, *Inhaled nitric oxide reduces pulmonary vascular resistance more than prostaglandin E(1) during heart transplantation*, Anesth Analg. 90(3):523-30 [2000]; Solina, A. *et al.*, *A comparison of inhaled nitric oxide and milrinone for the treatment of pulmonary hypertension in adult cardiac surgery patients*, J Cardiothorac Vasc. Anesth. 14(1):12-17 [2000]; Fullerton, D.A. *et al.*, *Effective control of pulmonary vascular resistance with inhaled nitric oxide after cardiac operation*, J Thorac Cardiovasc Surg 111(4):753-62, discussion 762-3 [1996]). The concentration in the gas mixture of nitric oxide (NO) is preferably about 1 to 100 ppm NO, more preferably about 4 to 80 ppm NO, and most preferably about 20 to 40 ppm NO. The gas mixture also contains appropriate concentrations of oxygen and nitrogen and/or other inert gases, such as carbon dioxide, helium or argon. Optionally, gaseous anesthetics, such as nitrous oxide (N₂O), xenon, and halogenated volatile anesthetics (HVAs), e.g., halothane, sevoflurane, and isoflurane, are also included in the gas mixture when general anesthesia is indicated. General anesthesia is indicated, for example, when administration of the potassium channel activator (and/or the medicant or chemotherapeutic agent) is by intracarotid infusion; general anesthesia is typically not required using intravenous or other delivery routes. The skilled practitioner is aware of evidence that HVAs can inhibit soluble guanylyl cyclase activity. (See, Masaki, E., *Halogenated volatile anesthetics inhibit carbon monoxide-stimulated soluble guanylyl cyclase activity in rat brain*, Acta Anaesthesiol. Scand. 44(3):321-25 [2000]; Masaki E. and Kondo I, *Methylene blue, a soluble guanylyl cyclase inhibitor, reduces the sevoflurane minimum alveolar anesthetic concentration and decreases the brain cyclicguanosine monophosphate content in rats*, Anesth. Analg. 89(2):484-89 [1999]). Consequently, an HVA is not the preferred choice of inhalable anesthesia for use with a guanylyl cyclase activator in accordance with the method.

Nitric oxide donors are compounds that produce NO-related physiological activity when applied to biological systems. Thus, NO-donors can mimic an endogenous NO-related response or substitute for an endogenous NO deficiency. The skilled artisan is aware that in biological systems there are at least three redox states of NO that can be released by various NO donors (NO⁺, NO⁰, or NO⁻), all of which are encompassed by the terms "nitric oxide" or "NO" for

purposes of the present invention. The redox state of NO makes a substantial difference to the NO donors reactivity towards other biomolecules, the profile of by-products, and the bioresponse (Feelisch, M., *The use of nitric oxide donors in pharmacological studies*, Naunyn-Schmiedebergs Arch. Pharmacol. 358:113-22 [1998]). Some classes of NO donors
5 require enzymatic catalysis, while others produce NO non-enzymatically; some NO donors require reduction, for example by thiols, and some oxidation, in order to release NO.

Preferred examples of nitric oxide donors include organic nitrate compounds, which are nitric acid esters of mono- and polyhydric alcohols. Typically, these have low water solubility, and stock solutions are prepared in ethanol or dimethyl sulfoxide (DMSO). Examples are
10 glyceryl trinitrate (GTN) or nitroglycerin (NTG), pentaerythrityl tetranitrate (PETN), isosorbide dinitrate (ISDN), and isosorbide 5-mononitrate (IS-5-N). Administration of organic nitrates can be done intravenously, intraperitoneally, intramuscularly, transdermally, or in the case of PETN, ISDN, NTG, and IS-5-N, orally.

Other preferred examples are S-nitrosothiol compounds, including
15 S-nitroso-N-acetyl-D,L-penicillamine (SNAP), S-nitrosoglutathione (SNOG), S-nitrosoalbumin, S-nitrosocysteine. S-nitrosothiol compounds are particularly light-sensitive, but stock solutions kept on ice and in the dark are stable for several hours, and chelators such as EDTA can be added to stock solutions to enhance stability. Administration is preferably by an intravenous or intra-arterial delivery route.

Other preferred examples of nitric oxide donors include sydnonimine compounds, such
20 as molsidomine (N-ethoxycarbonyl-3-morpholino-sydnonimine), linsidomine (SIN-1; 3-morpholino-sydnonimine or 3-morpholinylsydnoneimine or 5-amino-3morpholinyl-1,2,3-oxadiazolium, e.g., chloride salt), and pirsidomine (CAS 936). Stock solutions are typically prepared in DMSO or DMF, and are stable at 4°C to room
25 temperature, if protected from light. Linsidomine is highly water soluble and stable in acidic solution in deoxygenated distilled water, adjusted to about pH 5, for an entire day. At physiological pH, SIN-1 undergoes rapid non-enzymatic hydrolysis to the open ring form SIN-1A, also a preferred nitric oxide donor, which is stable at pH 7.4 in the dark. Administration is preferably by an intravenous or intra-arterial delivery route.

Also useful as nitric oxide donors are iron nitrosyl compounds, such as sodium nitroprusside (SNP; sodium pentacyanonitrosyl ferrate(II)). Aqueous stock solutions are preferably made freshly in deoxygenated water before use and kept in the dark; stability of stock solutions is enhanced at pH 3-5. Inclusion in the delivery buffer of a physiologically compatible thiol, such as glutathione, can enhance release of NO. SNP is administered by intravenous infusion, and the skilled practitioner is aware that long-term use is precluded by the release of five equivalents of toxic CN-per mole SNP as NO is released.

A most preferred nitric oxide donor is chosen from among the so-called NONOate compounds. The NONOates are adducts of NO with nucleophilic residues (X^-), such as an amine or sulfite group, in which an NO dimer is bound to the nucleophilic residue via a nitrogen atom to form a functional group of the structure $X[-N(O)NO]^+$. The NONOates typically release NO at predictable rates largely unaffected by biological reactants, and NO release is thought to be by acid-catalyzed dissociation with the regeneration of X^- and NO. This property is particularly useful in accordance with the inventive methods of selectively delivering a medicant, because abnormal brain regions and malignant tumors can typically be relatively hypoxic and possess a relatively low ambient pH (e.g., pH 6.5-7.0), which concentrates release of NO selectively in the microvasculature of the abnormal brain region or malignant tumor.

NONOates include most preferably diethylamine-NONOate (DEA/NO; N-Ethylethanamine: 1,1-Diethyl-2-hydroxy-2-nitrosohydrazine (1:1) or 1-[N,N-diethylamino]diazene-1-ium-1,2-diolate). Other preferred NONOates include diethylene triamine-NONOate (DETA/NO; 2,2'-Hydroxynitrosohydrazino]bis-ethanamine), spermine-NONOate (SPER/NO; N-(4-[-1-(3-Aminopropyl)-2-hydroxy-2-nitrosohydrazino]butyl)-1,3-propanediamine), propylamino-propylamine-NONOate (PAPA/NO; 3-(2-Hydroxy-2-nitroso-1-propylhydrazino)-1-propanamine or (Z)-1-[N-(3-aminopropyl)-N-(n-propyl)amino]diazene-1-ium-1,2-diolate), MAHMA-NONOate (MAHMA/NO; 6-(2-Hydroxy-1-methyl-2-nitrosohydrazino)-N-methyl-1-hexanamine), dipropylenetriamine-NONOate (DPTA/NO; 3,3'-(Hydroxynitrosohydrazino)bis-1-propanamine), PIPERAZI/NO, proli-NONOate (PROLI/NO; 1-([2-carboxylato]pyrrolidin-1-yl)diazene-1-ium-1,2-diolate-

methanol, e.g., disodium salt), SULFO-NONOate (SULFO/NO; hydroxydiazenesulfonic acid 1-oxide, e.g., diammonium salt), the sulfite NONOate (SULFI/NO), and Angelis salt (OXI/NO).

Almost all NONOate compounds are highly soluble in water, and aqueous stock solutions are prepared in cold deoxygenated 1 to 10 mM NaOH (preferably about pH 12) just prior to use. Alkaline stock solutions are stable for several hours if kept on ice in the dark. The characteristic UV absorbance of NONOates can be used for spectrophotometric quantification of NONOate in aqueous solutions. NONOates are preferably administered intravenously or intra-arterially.

Nitric oxide donors have different potencies (Ferraro, R. *et al.*, *Comparative effects of several nitric oxide donors on intracellular cyclic GMP levels in bovine chromaffin cells: correlation with nitric oxide production*, Br. J. Pharmacol. 127(3):779-87 [1999]). For example, DEA/NO is among the most potent nitric oxide donors, with a half-life of about 2 to 4 minutes; less potent are PAPA/NO ($t_{1/2}$ about 15 minutes), SPER/NO ($t_{1/2}$ about 34-40 minutes); even less potent are DETA/NO ($t_{1/2}$ about 20 hours) and SNAP ($t_{1/2}$ about 33 to 41 hours, although this can be shortened in the presence of a physiological reductant such as glutathione). SNP is also a potent NO donor. (See, Ferrero *et al.* [1999]; Salom, J.B. *et al.*, *Relaxant effects of sodium nitroprusside and NONOates in rabbit basilar artery*, Pharmacol. 57(2):79-87 [1998]; Salom, J.B. *et al.*, *Comparative relaxant effects of the NO donors sodium nitroprusside, DEA/NO and SPER/NO in rabbit carotid arteries*, Gen. Pharmacol. 32(1):75-79 [1999]; Salom, J.B. *et al.*, *Relaxant effects of sodium nitroprusside and NONOates in goat middle cerebral artery: delayed impairment by global ischemia-reperfusion*, Nitric Oxide 3(1):85-93 [1999]; Kimura, M. *et al.*, *Responses of human basilar and other isolated arteries to novel nitric oxide donors*, J. Cardiovasc. Pharmacol. 32(5):695-701 [1998]). Consequently, effective concentrations or doses of NONOates or other NO donors will vary over the preferred dose ranges for potassium channel activators described herein.

Stock solutions of NO donors are preferably made up freshly before use (at the appropriate pH for each particular NO donor), chilled on ice, and protected from light (e.g., by the use of darkened glass vials wrapped in aluminum foil), although organic nitrates can be stored for months to years if the vial is properly sealed. Preferably, immediately before

administration to the subject, final dilutions are prepared in pharmaceutically acceptable buffer and the final pH of the NO donor-containing buffer is checked for physiological suitability, especially when strongly acidic (e.g., hydrochloride salts) or alkaline (e.g., NONOates) stock solutions are used.

5 The product of NO exposure time and NO concentration largely determines the quality and magnitude of the biological response to exogenously supplied NO. Short-lived NO donors, such as DEA/NO, are most preferably administered by continuous infusion rather than by bolus to avoid delivering only a short burst of NO.

10 Also included among potassium channel activators are activators of any endogenous species of cyclic GMP-dependent protein kinase (PKG or cGK), that activates a potassium channel directly (e.g., by directly phosphorylating K_{Ca}) or indirectly (e.g., by phosphorylating another regulatory protein that directly modulates K_{Ca} activity). Included are activators of cGK I, cGK II, or other isoforms of cGMP-dependent protein kinase. (e.g., Smolenski, A. *et al.* [1998]). Useful examples of PKG activators include, but are not limited to, octobromo-cyclic
15 GMP (8Br-cGMP) and dibutyryl cyclic GMP.

 Included among useful potassium channel activators are pharmaceutically acceptable molecular conjugates or salt forms that still have activity as potassium channel activators as defined herein. An example is minoxidil sulfate, but other pharmaceutically acceptable salts
20 comprise anions other than sulfate, such as chloride, carbonate, bicarbonate, nitrate, or the like. Other embodiments of pharmaceutically acceptable salts contain cations, such as sodium, potassium, magnesium, calcium, ammonium, or the like. Other embodiments of useful potassium channel activators are hydrochloride salts.

 However, the potassium channel activator employed in the inventive methods is one
25 other than the vasodilator bradykinin (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg), or a polypeptide bradykinin analog, such as receptor mediated permeabilizer (RMP)-7 or A7 (e.g., Kozarich *et al.*, U.S. Patent No. 5,268,164 and PCT Application No. WO 92/18529). Other analogs of bradykinin include related peptide structures which exhibit the same properties as bradykinin but have modified amino acids or peptide extensions on either terminal end of the peptide. Examples of bradykinin analogs include [phe.sup.8 (CH.sub.2 NH) Arg.sup.9]-bradykinin,
30 Nacetyl [phe.sup.8 (CH.sub.2 --NH--Arg.sup.9] bradykinin and desArg9-bradykinin.

In accordance with the inventive methods, the potassium channel activator is administered by intravenous or intra-arterial injection or infusion. For treating an abnormal brain region, such as an intracranial tumor, the potassium channel activator is preferably administered by intracarotid infusion. Except where otherwise noted, the amount of potassium channel activator to be administered to the mammalian subject ranges from 0.075 to 1500 micrograms per kilogram body mass. For humans the range of 0.075 to 150 micrograms per kilogram body mass is preferred. As the skilled practitioner is aware, the physiological responses of individual patients to treatment with particular potassium channel activators will vary. For example, generally an effective amount of YC-1 for humans is about 15 to about 45 micrograms per kg body mass, and for nitric oxide donors generally about 15 to about 45 micrograms per kg body mass. However, the optimal amount for each individual for any particular potassium channel activator can be determined by routine means involving close physiological monitoring over the delivery period.

The dose can be administered in a bolus injection, but is preferably administered by infusion over a period of one to thirty minutes, and most preferably during a period of one to fifteen minutes. For example, in rats, a dose rate of about 0.75 to about 100 $\mu\text{g kg}^{-1} \text{min}^{-1}$ is most suitable. At dose rates above about 100 $\mu\text{g kg}^{-1} \text{min}^{-1}$ a concomitant fall in blood pressure has sometimes been observed. In humans, effective dose rates are about 0.075 to about 15 $\mu\text{g kg}^{-1} \text{min}^{-1}$, with cautious monitoring of blood pressure being advised. The practitioner skilled in the art is also cautious in regulating the total infusion volume, rate of liquid infusion, and electrolyte balance to avoid adverse physiological effects related to these. Some potassium channel activators, such as NS-1619, minoxidil, minoxidil sulfate, pinacidil, or diazoxide are not easily dissolved in water; in preparing these agents for administration, a suitable and pharmaceutically acceptable solvent, such as ethanol, can be used to dissolve the potassium channel activator prior to further dilution with an infusion buffer. The skilled practitioner is cautious in regulating the final concentration of solvent in the infusion solution to avoid solvent-related toxicity. For example, a final ethanol concentration in an infusion solution up to 5-10% (v/v) is tolerated by most mammalian subjects with negligible toxicity.

While the inventive method does not depend on any particular mechanism by which increased microvascular permeability to the medicant is achieved, it is thought that administration of the potassium channel activator increases potassium flux through potassium channels in endothelial cell membranes of the capillaries and arterioles delivering blood to abnormal brain regions and/or malignant tumors. This results in a loosening of tight junctions in the microvascular epithelium and/or increased pinocytotic activity, enhancing the uptake of medicants from the blood vessels. In practicing the inventive methods, it is not necessary to measure potassium channel activity (i.e., potassium cation flux therethrough). But the skilled artisan is aware that potassium flux can be measured by any suitable method, for example, by measuring cellular uptake of $^{42}\text{K}^+$ or $^{201}\text{Tl}^+$ or channel conductance using patch-clamp or microelectrode devices. (e.g., T. Brismar *et al.*, *Thallium-201 uptake relates to membrane potential and potassium permeability in human glioma cells*, Brain Res. 500(1-2):30-36 [1989]; T. Brismar *et al.*, *Mechanism of high K^+ and Tl^+ uptake in cultured human glioma cells*, Cell Mol. Neurobiol. 15(3):351-60 [1995]; S. Cai *et al.*, *Single-channel characterization of the pharmacological properties of the $\text{K}(\text{Ca}^{2+})$ channel of intermediate conductance in bovine aortic endothelial cells*, J. Membr. Biol. 163(2):147-58 [1998]).

The medicant is administered simultaneously or substantially simultaneously with the potassium channel activator, and the medicant is delivered by the blood stream selectively to the abnormal brain region and/or to the malignant cells compared to normal brain tissue or non-malignant cells. "Simultaneously" means that the medicant is administered contemporaneously or concurrently with the potassium channel activator. "Substantially simultaneously" means that the medicant is administered within about one hour after the potassium channel activator is last administered, preferably within about 30 minutes after, and most preferably, is administered simultaneously with the potassium channel activator. Alternatively, "substantially simultaneously" means that the medicant is administered within about 30 minutes before, and preferably within about 15 minutes before the potassium channel activator is first administered.

The methods of delivering a medicant to an abnormal brain region and/or to a malignant tumor in a mammalian subject are effective in selectively delivering any medicant across the microvascular of an abnormal brain region and/or malignant tumor. The medicant is a drug, i.e.,

a chemotherapeutic agent. Example of chemotherapeutic agents including therapeutic cytotoxic agents (e.g., cisplatin, carboplatin, methotrexate, 5-fluorouracil, amphotericin), naked DNA expression vectors, therapeutic proteins, therapeutic oligonucleotides or nucleotide analogs, interferons, cytokines, or cytokine agonists or antagonists, adrenergic agents, anticonvulsants, anti-trauma agents, or any neuropharmaceutical agent used to treat or prevent an injury or disorder of the brain. Chemotherapeutic agents also include ischemia-protective drugs such as N-methyl-D-aspartate (NMDA) receptor antagonists; antimicrobial agents, such as antibiotics; immunotoxins, immunosuppressants, boron compounds, monoclonal antibodies and specific antigen-binding antibody fragments (e.g., Fab, Fab', F(ab')₂, or F(v) fragments), and cytokines, such as interferons, interleukins (e.g., interleukin [IL]-2), tumor necrosis factor (TNF)- α , or transforming growth factors (e.g., TGF- β).

The medicant also includes anticancer chemotherapeutic agents. Typically, anticancer chemotherapeutic agents are cytotoxic agents, such as 5-fluorouracil, cisplatin, carboplatin, methotrexate, daunorubicin, doxorubicin, vincristine, vinblastine, or a cytotoxic alkylating agent, such as, but not limited to, busulfan (1,4-butanediol dimethanesulphonate; Myleran, Glaxo Wellcome), chlorambucil, cyclophosphamide, melphalan, or ethyl ethanesulfonic acid.

The anticancer chemotherapeutic agents are particularly useful in practicing the method of selectively delivering a medicant to a malignant tumor, in the brain or in any other tissue of the body, and in the method of treating a malignant tumor in a human subject.

Medicants also include any therapeutic viral particle, for example an adenovirus-derived or herpes simplex virus (HSV)-derived viral vector for delivering genetic material to a cellular target in vivo. Medicants also include diagnostic agents, such as imaging or contrast agents, for example, radioactively labeled substances (e.g., [⁹⁹Tc]-glucoheptonate), gallium-labeled imaging agents (e.g., gallium-EDTA), ferrous magnetic, fluorescent, luminescent, or iodinated contrast agents. Where suitable, any of the afore-mentioned medicants having anticancer activity can also be used in practicing the method of selectively delivering a medicant to a malignant tumor or the method of treating a malignant tumor in a human subject.

Thus, the medicant can be a molecular substance having a molecular weight between about 50 Daltons and about 250 kD. Or it can be a particle, such as a viral particle, having a diameter between about 50 to 250 nanometers.

This is by no means intended to be an exhaustive list of the kinds of medicants that can be employed in practicing the inventive methods. The medicant can be, but is preferably not, an agent that is highly lipid soluble and thus inherently able to penetrate cell membranes, for example nitrosourea.

5 The amount of medicant that is employed is within a conventional dose range for each medicant, however by practicing the inventive method, the increased transvascular permeability afforded can provide a greater selective therapeutic effect per dose or permit a lower effective dose to be used, if desired, for example to lessen systemic toxic effects from anti-cancer medication in a particular subject.

10 The medicant is administered by any appropriate method that can deliver it to the blood stream. Typically, this is by intravenous, intramuscular, or intra-arterial (including intracarotid) injection or infusion. However, for some applications other acceptable delivery routes can be used as long as the dose of medicant enters the blood stream substantially simultaneously with the potassium channel activator. Examples include ingestion (e.g., of a powder, suspension,
15 solution, emulsion, tablet, capsule or caplet); subcutaneous injection; stereotactic injection; or transdermal or transmucosal delivery by adhesive patch, suppository or gel for delivery through the skin, mucosa or epithelium of the mouth including the sublingual epithelium, the rectum, or the vaginal epithelium.

20 Alternatively, the medicant is administered together with the potassium channel activator in a pharmaceutical composition of the present invention. The inventive pharmaceutical composition comprises a combination of a potassium channel activator, other than bradykinin or a bradykinin analog, as described above, formulated in a pharmaceutically acceptable solution together with a medicant, as described above, for delivery by intravascular infusion or bolus injection into a mammal, such as a human. The solution is thus suitably balanced, osmotically
25 (e.g., about 0.15 M saline) and with respect to pH, typically between pH 7.2 and 7.5; preferably the solution further comprises a buffer, such as a phosphate buffer (e.g., in a phosphate buffered saline solution). The solution is formulated to deliver a dose rate of about 0.075 to 1500 micrograms of potassium channel activator per kilogram body mass in a pharmaceutically acceptable fluid volume over a maximum of about thirty minutes. For human subjects, the
30 solution is preferably formulated to deliver a dose rate of about 0.075 to 150 micrograms of

potassium channel activator per kilogram body mass in a pharmaceutically acceptable fluid volume over a period of up to about thirty minutes.

The invention also relates to a kit for enhancing the delivery of a medicant to an abnormal brain region and/or to a malignant tumor. The kit is an assemblage of materials or components, including a potassium channel activator, other than bradykinin or a bradykinin analog, as described above. In addition, the kit contains instructions for using the potassium channel activator to enhance the permeability of abnormal microvascular, including neomicrovasculature, to a medicant in general, or alternatively, to a particular medicant. Optionally, the kit also contains other components, such as a particular medicant in any pharmaceutically acceptable formulation, or paraphernalia for injection or infusion, for example syringes, infusion lines, clamps, and/or infusion bags/bottles, which can contain a pharmaceutically acceptable infusible formulation of the potassium channel activator with or without a particular medicant also contained therein. The materials or components assembled in the kit can be provided to the practitioner stored in any convenient and suitable ways that preserve their operability and utility. For example the components can be in a dissolved, dehydrated, or lyophilized form; they can be provided at room, refrigerated or frozen temperatures.

The foregoing descriptions of the methods and kits of the present invention are illustrative and by no means exhaustive. The invention will now be described in greater detail by reference to the following non-limiting examples.

EXAMPLES

Example 1: Methods

Malignant Cell Line and Tumor Implantation. A rat glioma cell line, RG2, was used for implantation of experimental brain tumors in female Wistar rats. The techniques for RG2 cell propagation and maintenance in tissue culture have been described (Sugita, M. and Black, K.L., *Cyclic GMP-specific phosphodiesterase inhibition and intracarotid bradykinin infusion enhances permeability into brain tumors*, Cancer Res. 58(5):914-20 [1998]; Inamura et al. [1994]; Nakano, S. et al., *Increased brain tumor microvessel permeability after intracarotid*

bradykinin infusion is mediated by nitric oxide, Cancer Res. 56(17):4027-31 [1996]). Briefly, RG2 cells derived from a rat glioma are kept frozen until use, then are thawed and maintained in a monolayer culture in F12 medium with 10% calf serum. In some experiments C6 glioma cells were used.

5 The Wistar rats (approximately 140-160 g body weight) were anesthetized with intra-peritoneal ketamine (50 mg/kg), and glial cells (1×10^5) were implanted into the right hemisphere, but not the contralateral hemisphere, by intracerebral injection suspended in 5 μ L F12 medium (1-2% methylcellulose) by a Hamilton syringe. The implantation coordinates were 3-mm lateral to the bregma and 4.5 mm deep to the dural surface.

10 Intracarotid Infusion of Potassium Channel Activators. Seven days after implantation of RG2 cells, the rats were anesthetized as described above and prepared for permeability studies. Animals were infused with either NS-1619 (a selective large conductance Ca^{2+} -activated K^+ channel activator; RBI, Natick, MA) or minoxidil sulfate (a K_{ATP} channel activator) into the right carotid artery at a dose rate of $5.3 \mu\text{g kg}^{-1} \text{ min}^{-1}$ (in $53.3 \mu\text{L/min}$) for 15 minutes, in an infusion
15 vehicle of PBS, pH 7.4; 5% (v/v) ethanol. Ethanol (25% [v/v]) was used to dissolve the potassium channel activators before dilution in PBS. For blood volume studies, 5 and 14 minutes after the start of the intracarotid infusion of potassium channel activator compounds, [^{14}C] Dextran (100 $\mu\text{Ci/kg}$; Dupont-New England Nuclear Co., Boston, MA) was injected as an intravenous bolus and maintained for 1 minute and 10 minutes to obtain two different time
20 points. For regional permeability studies, 5 minutes after the start of the intracarotid infusion of vasoactive compounds, 100 $\mu\text{Ci/kg}$ of [^{14}C] α -aminoisobutyric acid (Dupont-New England Nuclear Co., Boston, MA) was injected as an intravenous bolus into the right femoral vein. A peristaltic withdrawal pump was used to withdraw femoral arterial blood at a constant rate of 0.083 mL/min immediately after the injection of the tracer to determine serum radioactivity.
25 Fifteen minutes after the intracarotid infusion, rat decapitated and the brain rapidly removed and frozen for quantitative autoradiography.

 In permeability studies with nitric oxide (NO) donors, intracarotid infusion of NO donors was done as described above at a dose rate of $2.66 \mu\text{g min}^{-1} \text{ kg}^{-1}$ for 15 minute. Nitric oxide donors included sodium 2-(N,N-diethylamino)-diazemolate-2-oxide (DEA/NO), a nitric

oxide-donor with a half-life of 2.1 min or PAPA/NO ([Z]-1-[N-[3-Amino propyo]-N-[N-propyo amino] diazen-1-ium-1,2-diolate; (Alexis Corp.), a nitric oxide-donor with a half-life of 15 minutes. DEA/NO or PAPA/NO were dissolved in PBS and administered to RG2 glioma-bearing rats to determine permeability (K_i) of [14 C]-AIB without affecting the physiological parameters. [14 C]-AIB was administered intravenously as a bolus and K_i determined. Physiological parameters were monitored during the experiments.

Unidirectional Transport Constant (K_i). The unidirectional transfer constant K_i for [14 C] α -aminoisobutyric acid (AIB) was measured in normal tissue and tumor tissue as an indicator of permeability across the blood-tumor and blood-brain barriers. Quantitative autoradiography was used to obtain K_i values ($\mu\text{L g}^{-1} \text{min}^{-1}$). The initial rate for blood-to-brain transfer was calculated using a previously described equation. (Ohno, K, *et al.*, *Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat*, Am. J. Physiol. 235(3):H299-307, [1978]; Inamura, T., *et al.*, *Bradykinin selectively opens blood-tumor barrier in experimental brain tumors*, J. Cereb. Flow Metab. 14(5):862-70 [1994]). Quantitative data were analyzed using, two group t-test and two-group Fishers-exact test of equal proportions or equal means (equal numbers) at 90% power requires a minimum of 6 animals in each group to achieve statistical significance. Multiple treatment groups were compared with control group by ANOVA and P values determined by post-hoc Bonferroni test.

Dose-dependence studies. NS-1619 was dissolved in 25% ethanol and diluted with PBS to obtain various concentrations for infusion. NS-1619 was administered by intracarotid infusion (dose rates: 0, 13, 26.5, 53, 80, 100 and 110 $\mu\text{g kg}^{-1} \text{min}^{-1}$; all at 53.3 $\mu\text{L/min}$) to RG2 glioma-bearing rats to determine a dose that produces increased permeability (K_i) of [14 C]-AIB, which was administered intravenously. K_i was determined as described above. Physiological parameters were monitored during the experiments.

Inhibition studies. Since NS-1619 increased permeability, the specificity of its effect was examined using the specific K_{Ca} channel inhibitor, iberiotoxin (RBI, Natick, MA; ([IBTX] was diluted in saline to a final stock concentration of 100 $\mu\text{g/mL}$). IBTX ($2.3 \mu\text{g kg}^{-1} \text{min}^{-1}$) was

co-infused with NS-1619 ($26.5 \mu\text{g kg}^{-1} \text{min}^{-1}$) to block K_{Ca} channel-induced permeability in abnormal capillaries in the RG2 glioma rat model. Seventeen rats were used for these studies (3 vehicle-only control [i.e., PBS + 5% (v/v) ethanol]; 3 IBTX; 8 NS-1619; 3 NS-1619 + IBTX).

5 In other experiments, IBTX ($0.2 \mu\text{g min}^{-1} \text{kg}^{-1}$ for 15 min) was co-infused with the nitric oxide donor DEA/NO ($2.66 \mu\text{g min}^{-1} \text{kg}^{-1}$ for 15 min) to block K_{Ca} channel-induced permeability in abnormal capillaries in the RG2 glioma rat model. Thirteen rats were used for these studies (4 vehicle-only control; 3 DEA/NO, 3 PAPA/NO, and 3 DEA/NO+IBTX).

10 In other in vivo permeability experiments using Wistar rats harboring intracranial RG2 tumors, as described above, the unidirectional transport constant (K_i) for [^{14}C]-AIB to the tumor center and tissue surrounding tumor was determined after intracarotid infusion of bradykinin ($10 \mu\text{g min}^{-1} \text{kg}^{-1}$ for 15 min) or minoxidil sulfate ($26.6 \mu\text{g min}^{-1} \text{kg}^{-1}$ for 15 min) or co-infusion of bradykinin with minoxidil sulfate for 15 min. Physiological parameters were monitored during the experiments. The selective K_{ATP} inhibitor, glibenclamide ($13.3 \mu\text{g min}^{-1} \text{kg}^{-1}$ for 15 min) was
15 used to determine whether inhibition of K_{ATP} channel blocks bradykinin-inducible or minoxidil sulfate-inducible increases in blood-tumor barrier permeability.

In other experiments, RG2 glioma cells were implanted into the right hemisphere of rat brains as described above. Seven days after implantation, regional permeability study was performed by intracarotid infusion of octobromo-cyclic GMP (8Br-cGMP, $16.7 \mu\text{g kg}^{-1} \text{min}^{-1}$),
20 an activator of cyclic GMP-dependent protein kinase (PKG), without or with PKG inhibitors (KT5823, $6.77 \mu\text{g kg}^{-1} \text{min}^{-1}$; or Rp-pCPT-cGMP, $60 \mu\text{g kg}^{-1} \text{min}^{-1}$). Saline or 2% DMSO was infused into rats in a control group. At the termination of the study, rats were killed under anesthesia, and brains were removed for measurement of K_i for [^{14}C]-AIB ($\mu\text{L g}^{-1} \text{min}^{-1}$). Western blot analysis was also used to compare PKG expression levels in normal brain and
25 tumor tissue.

Quantitative autoradiography and calculations of K_i for [^{14}C]-AIB were performed as described above, according to Ohno *et al.* (1978).

Immunohistochemical analysis for K_{Ca} and K_{ATP} channels. Brain sections (12 μm thick)
30 obtained from the permeability studies were incubated with 1:100 dilution of affinity-purified

K_{Ca} channel antibody (Alomone Labs, Jerusalem, Israel) for 1 hour, and biotinylated horse anti-mouse immunoglobulin (Vector Laboratories, Burlingame, CA) for 30 minutes. After washing 3 times with PBS, the peroxidase sites were visualized using an avidin:biotinylated enzyme complex (ABC) kit (KCa). For immunolocalization of K_{ATP}, tissue sections as described above were incubated overnight at 4°C with rabbit anti-mouse Kir 6.2 antiserum (1:200 dilution; anti-serum generously provided by Dr. Susumu Seino), which antiserum is cross-reactive with human Kir 6.2 and was prepared as previously described (Suzuki, M. *et al.*, *Immuno-localization of sulphonylurea receptor 1 in rat pancreas*, *Diabetologia* 42(10):1204-11 [1999]). Kir 6.2 is a potassium inward rectifier (Kir) protein component of mammalian K_{ATP}. Visualization of bound rabbit anti-mouse Kir 6.2 antibody was done after washing 3 times with PBS and binding with secondary antibody (rhodamine-labeled anti-rabbit IgG [1:200 dilution]; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) as directed by the manufacturer, and examining with a confocal fluorescence microscope.

Transmission Electron Microscopy (TEM). Rat brain tissue was prepared for TEM analysis by the following procedures. After experiments involving intracarotid infusion of potassium channel activators, inhibitors, horse radish peroxidase (HRP), and/or vehicle control buffers, rats were infusion-fixed from the heart first with PBS (50-100 mL) followed with 1.0% glutaraldehyde (250 mL). The brain tissue was cut coronally to expose the tumor region, and the region of interest was selected, sliced into small pieces of about 1 mm thickness, and was immersion-fixed in 1.0% glutaraldehyde, at 4°C for 2 hours. The sample was rinsed in 5% sucrose / 0.1 M PBS at 4°C, overnight, with continuous shaking and changes of the solution. The samples then were immersion-fixed with 1% OsO₄ at 4°C for 2 hours with continuous shaking. The sample was then dehydrated with an increasing concentration (50-100%) of ethanol at 4°C for 15 minutes with constant shaking and frequent changes of solution. Samples were infiltrated with propylene oxide, and then with epon at room temperature with shaking. Embedding was done at 60°C over 48 hours. Semi-thin sections (about 30-50 µm thick) were taken with a microtome equipped with a diamond-edge blade. Finally, ultrathin sections (about 1-10 nm thick) were prepared with a microtome and stained with uranyl acetate for 45-60

minutes, lead citrate for 5 minutes and processed for TEM analysis. T e n capillaries in each treatment group were selected and photographed at low magnification (total 90 capillaries). The basic morphology of the capillaries was examined by way of measuring and calculating the following parameters which represent the basic profile of the capillary: abluminal circumference, luminal circumference, total area of the capillary (excluding nuclei and vacuoles), and mean thickness of the capillary.

In a separate study, the density of the vesicles was determined for three vessels selected from each rat (each treatment group contained 5-6 rats) by taking from each blood vessel four electron micrographs as a test zone at high magnification. The test zones were selected randomly, such as at 3, 6, 9, and 12 o'clock on the EM screen. The areas of the test zones were measured, and the number of vesicles was counted by a person who was not aware of the background of the micrographs. Vesicular density was expressed as the number of vesicles per square micrometer of cytoplasm. The proportion of the total vesicular area to the cytoplasmic area was also determined using the same micrographs: total vesicular area was measured and the proportion to the cytoplasm which included those vesicles was calculated and expressed as percentage. The mean diameter of the vesicles was also calculated.

Morphological changes resulting from the treatments were examined by selecting six tight junctions from each rat (five rats were in each treatment group for a total 270 tight junctions). The tight junctions were photographed at high magnification. The analysis of tight junction was by comparing "cleft index" and "cleft area index" for each tight junction. The cleft index was expressed by the following formula: (length of unfused segments) ÷ (length of junctions). (Stewart, 1987). The cleft area index was expressed by the formula: (area of unfused segments) ÷ (length of junction).

Temporary Middle Cerebral Artery (MCA) occlusion. MCA occlusion was carried out as described by Liu, Y. *et al.*, *The time course of glucose metabolism in rat cerebral ischemia with middle cerebral artery occlusion-reperfusion model and the effect of MK-80*, *Neurological Research* 18 (6): 505-508 (1996) with slight modifications. Briefly, the right MCA was occluded temporarily with a silicone rubber cylinder inserted from the bifurcation of the intracarotid artery after ligation of ipsilateral common and external carotid arteries. The cylinder

is made of 4-0 nylon 17 mm long surgical thread, coated with silicone mixed with a hardener to grade the diameter of the distal 5 mm to 0.25-0.30 mm. The thread was inserted into the intracarotid artery through the external carotid artery near the bifurcation and ligated at the point of insertion. The silicone rubber cylinder reached the proximal portion of the anterior cerebral artery. The origin of the right MCA and posterior-communicating artery were occluded by the thread. Following the surgery, animals were immobilized by means of loose fitting Pasteur casts and allowed to recover from anesthesia. The thread was pulled out from the intracarotid artery after 1 hour or 2 hours of ischemia to allow reperfusion of the ischemic tissue with blood. Potassium channel activator(s) and/or inhibitor(s) were injected by intracarotid infusion after 45 minutes of reperfusion for an additional 15 minutes.

In some experiments, Evans blue dye was injected intravenously after 50 minutes of reperfusion (five minutes after commencing administration of potassium channel activator and/or inhibitor). Ten minutes after injection of Evans blue, the rat was perfused with 200 mL PBS through the heart to wash off excess Evans blue dye from the brain microvessels.

Example 2: Results

Potassium Channel Activators Selectively Increase Transport Across the Blood-tumor Barrier.

When Wistar rats bearing implanted glioma cells were infused with either NS-1619 or minoxidil sulfate, at $7.5 \mu\text{g kg}^{-1} \text{ min}^{-1}$ for 15 minutes, the unidirectional transport constant K_i for [^{14}C] α -aminoisobutyric acid (AIB) was significantly increased by NS-1619 and minoxidil sulfate with respect to transport across the neovasculature forming the blood-tumor barrier, but not with respect to transport across normal brain microvasculature (Figure 12A and Figure 12B). These results demonstrated that activation of potassium calcium channels selectively increases the permeability of molecules across the capillaries of solid malignant tumors compared to capillaries supplying normal brain tissue.

Increasing the dose of NS-1619 resulted in an increase in the unidirectional transfer constant K_i for [^{14}C] α -aminoisobutyric acid in RG2 glioma capillaries in a dose-dependent manner (Figure 13). At higher doses (100 and 110 $\mu\text{g/kg/min}$) a significant drop in the arterial blood pressure of the rats was observed. The numbers of rats used in each group is shown in parentheses in Figure 13.

The specificity of this effect was demonstrated, because the ability of NS-1619 to increase the unidirectional transfer constant K_i for [^{14}C] α -aminoisobutyric acid was inhibited by the K_{Ca} -channel-specific inhibitor iberitoxin (IBTX; Figure 14). The K_i was determined in RG2 tumor-bearing rats using [^{14}C]-AIB with NS-1619 ($26.5 \mu\text{g min}^{-1} \text{kg}^{-1}$) with or without IBTX ($2.3 \mu\text{g kg}^{-1} \text{min}^{-1}$; $n=3$), for 15 minutes. Increase of K_i in response to NS-1619 infusion ($n=8$; $** P<0.001$ compared with PBS with or without 5% ethanol) was attenuated by IBTX co-treatment. IBTX alone at the dose investigated did not affect the brain-tumor barrier permeability of abnormal capillaries. However, IBTX significantly ($n=3$, $** P<0.001$ compared with NS-1619-treated group) decreased NS-1619-induced increase of permeability (K_i), indicating a potassium channel-specific effect. Controls receiving PBS plus 5% ethanol were indistinguishable from controls receiving PBS minus ethanol.

A comparable increase in blood-tumor barrier permeability was obtained when the soluble guanylyl cyclase activator YC-1 was administered (Figure 1). IBTX and a selective inhibitor of soluble guanylyl cyclase, 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), attenuated the enhancement of K_i by YC-1, showing it was K_{Ca} -mediated.

Infusion of minoxidil sulfate resulted in a significant increase in K_i ($28.3 \pm 6.0 \mu\text{L/g/min}$; $P<0.001$), compared to the vehicle control group (Figure 7). This increase in blood-tumor permeability was attenuated by the K_{ATP} channel inhibitor glibenclamide, which significantly attenuated ($K_i = 12.7 \pm 2.0 \mu\text{L/g/min}$) the effect of minoxidil sulfate. Thus, the K_i increases with minoxidil sulfate were due to activation of K_{ATP} channels, which selectively enhanced blood-tumor barrier permeability. The increase in permeability resulting from treatment with minoxidil sulfate was comparable to that caused by the K_{Ca} activator bradykinin ($K_i = 34 \pm 8.0 \mu\text{L/g/min}$), and a significant additive effect on permeability ($K_i = 42 \pm 6 \mu\text{L/g/min}$; $P<0.05$) was achieved with combination treatment with bradykinin and minoxidil sulfate as compared to individual treatment groups (Figure 7).

The co-infusion with glibenclamide failed to block bradykinin-inducible K_i increase (Figure 8) is consistent with other studies showing bradykinin does not modulate K_{ATP} channels. However, the K_{Ca} channel antagonist, IBTX, significantly attenuated bradykinins effect ($K_i = 17.7 \pm 6 \mu\text{L/g/min}$; $P<0.01$) indicating that the K_i increase was due to activation of K_{Ca} and not K_{ATP} channels by bradykinin (Figure 8).

Minoxidil sulfate-induced effect was significantly attenuated by glibenclamide ($K_i = 12.7 \pm 2 \mu\text{L/g/min}$; $P < 0.001$; Figure 9). However, this effect was not blocked by IBTX indicating that K_{ATP} channels mediate minoxidil sulfate-induced permeability. These results imply independent pathways for blood-tumor barrier permeability, one regulated by K_{Ca} and the other by K_{ATP} channels in the microcapillary of the brain tumor.

Nitric oxide donors also increased the permeability of the blood-tumor barrier. Figure 2 shows that RG2 glioma tissue was stained in vivo by Evans blue stain (MW 960.82) in DEA/NO-treated Wistar rats (Figure 2B) compared to PBS-treated controls (Figure 2A). These results were comparable to the results obtained by in vivo staining by Evans blue using NS-1619 or YC-1 (data not shown).

Figure 3 shows that K_i increased markedly in response to DEA/NO and PAPA/NO ($K_i = 32 \pm 9.0 \mu\text{L g}^{-1} \text{min}^{-1}$ and $36.4 \pm 4.0 \mu\text{L g}^{-1} \text{min}^{-1}$, respectively) compared to controls (saline). However, co-treatment with IBTX attenuated the effect of infusions of DEA/NO ($K_i = 15.3 \pm 2.3 \mu\text{L g}^{-1} \text{min}^{-1}$; $P < 0.001$) or PAPA/NO ($K_i = 15.3 \pm 1.7 \mu\text{L g}^{-1} \text{min}^{-1}$; $P < 0.001$) and, showing that the effect was K_{Ca} -mediated. IBTX alone at the dose investigated did not affect the brain-tumor barrier permeability of abnormal capillaries.

Western blots revealed PKG expression in both normal brain and tumor tissue. PKG activator 8Br-cGMP increased K_i values compared with vehicle-only controls ($K_i = 22.1 \pm 6.6 \mu\text{L g}^{-1} \text{min}^{-1}$ versus $14.2 \pm 5.1 \mu\text{L g}^{-1} \text{min}^{-1}$, $p < 0.05$). These results imply that endogenous production of cGMP, which activates PKG, selectively increases blood-tumor barrier permeability, presumably by PKG-mediated activation of K_{Ca} .

Immunohistochemical Analysis Shows Potassium Channels Are More Abundant in Neovasculature and Malignant Cells Compared to Normal Tissue.

K_{Ca} channel protein was immunolocalized using a specific antibody as described above. Immunohistochemical analysis showed that K_{Ca} channels were selectively increased in tumor tissue and tumor capillaries in RG2 bearing rat brain sections, compared to sections of normal contralateral tissue (Figure 15). Similarly, immunolocalization of K_{ATP} using a K_{ATP} -specific antibody showed that K_{ATP} channels were selectively increased in tumor tissue and tumor capillaries in RG2 tumor-bearing and C6-tumor-bearing rat brain sections (Figure 16). These

immunohistochemical results are consistent with the permeability data in which activation of K_{Ca} channel by NS-1619, or K_{ATP} by minoxidil, selectively opened the blood-tumor barrier.

Together, the permeability and immunohistochemical data demonstrate that compounds that activate potassium channels can be used to selectively increase delivery of anti-tumor compounds to malignant tumor tissue.

Transmission Electron Microscopic studies. Transmission electron microscopic (TEM) studies revealed accelerated formation and movement of pinocytotic vesicles along the luminal-abluminal axis of capillary endothelium, as well as tumor cells, following intracarotid infusion of K_{Ca} activators NS-1619 and bradykinin, compared to a PBS control (Figure 4). Quantitative analysis showed that both bradykinin and NS-1619 significantly increased the number of vesicles per unit surface area of nucleus-free cytoplasm, compared to the PBS control. The pinocytotic vesicles had an average diameter of 75-80 nm. Invagination of luminal membrane of tumor capillary endothelial cells gives rise to arrays of pinocytotic vesicles, which migrate along a luminal-abluminal axis in endothelial cytoplasm (E). These vesicles dock and fuse with the basement membrane, releasing their contents on abluminal side of endothelial cell membrane. Cells from the treatment group appear to have intact basal membrane (BM) and endothelial tight junctions. Transport pinocytotic vesicles (PV) are present near luminal (L) as well as abluminal (Ab) areas (Figure 4). Cells from gliomas after infusion of either bradykinin or NS-1619 have intact basal membrane and endothelial tight junctions (TJ). (E.g., Figure 5). Additional TEM studies revealed the presence of electron dense horse radish peroxidase (HRP; protein marker with a molecular weight of about 40,000) within the arrays of pinocytotic vesicles in endothelial cells of brain tumor capillaries and showed HRP being transported from the luminal to the abluminal area of the endothelium to the tumor cells after the K_{Ca} activator bradykinin was co-infused with HRP into rats with RG2 tumors. (Figures 5 and 6). This evidence of HRP-laden transport vesicles implies that transendothelial vesicular transport is a significant cellular mechanism for drug delivery to the tumor cells.

Additional TEM studies with tumor-bearing rats infused with the potassium channel activator bradykinin, and intravenously injected with the tracer horseradish peroxidase (HRP), revealed the presence of electron dense HRP within the arrays of pinocytotic vesicles in

endothelial cells of brain tumor capillaries (Figure 5; P = plasma membrane). Following bradykinin infusion there was an increase in the number of HRP-laden vesicles (observed in the tumor cells compared to PBS-treated tumor cells Figure 6; arrows), implying that vesicular transport is a primary cellular mechanism for drug delivery to the tumor cells, once the drug molecules cross the capillary endothelium into the brain tumor mass.

No significant difference was seen in any of the examined morphological parameters between the vehicle control and the bradykinin (BK) infusion group, but there was a significant difference in these parameters in comparing the different kinds of tissue examined. Abluminal and luminal circumference, area of the capillary, and mean thickness of the capillary of RG2 tumor and C6 tumor were significantly larger than those of normal brain basal ganglia. However, a significant increase in density and proportion of vesicle area in the basal ganglia was observed in bradykinin-treated rats in RG2 and C6 tumor area as compared to the untreated rats (Table 1).

Table 1. Density and proportion of the area of vesicles to endothelial cytoplasm.

Tissue ^a	Infusion ^{aa}	Density of the vesicles (number/m ²) ^b	Total area of the vesicles (%) ^c
BG	PBS	2.02 ± 0.35 (n = 5)	0.65 ± 0.26 (n = 6)
	BK	1.75 ± 0.90 (n = 5)	0.54 ± 0.35 (n = 6)
RG2 tumor	PBS	3.29 ± 0.66 (n = 5)	1.30 ± 0.36 (n = 6)
	BK	9.88 ± 2.93 d (n = 6)	3.71 ± 0.96d (n = 6)
C6 tumor	PBS	5.46 ± 3.29 (n = 5)	1.34 ± 0.57 (n = 6)
	BK	11.90 ± 2.40d (n = 5)	4.31 ± 1.34 ^d (n = 6)

^a BG = basal ganglia.

^{aa} PBS = phosphate buffer saline vehicle control; BK = PBS + bradykinin.

^b Values are means ± SD; n = number of rats.

^c Values are means ± SD; n = number of capillaries.

^d Significant difference from saline control group at p < 0.01

Potassium channel activators increase permeability in abnormal brain capillaries of ischemic brain region.

In preliminary MCA occlusion/reperfusion studies it was shown that the K_{Ca} activator bradykinin increases permeability in infarct tissue after transient-ischemia. NOS activity was significantly elevated in transient ischemia-reperfusion rat models (data not shown), corresponding to the ability of bradykinin to increase permeability in ischemic capillaries (Figure 10B). As shown in Figure 10B, the permeability of microvasculature in ischemic brain regions exhibited enhanced responsiveness to potassium channel activator after two hours of MCA occlusion, compared to normal brain microvasculature (i.e., contralateral tissue). In contrast, Figure 10A shows that the permeability of brain microvasculature was not responsive to a potassium channel activator after only one hour of MCA occlusion. This indicates that properties of the microvasculature are changed by prolonged ischemia as the tissue becomes increasingly abnormal.

Using the ischemia-reperfusion rat model, it was directly observed that enhanced permeability to Evans blue dye was regulated, by potassium channels in ischemic brain regions. In Figure 11, coronal brain sections show Evans blue (EB) staining within the tumor tissue. The uptake of Evans blue dye is a known qualitative measure of blood-brain barrier/blood-tumor barrier permeability. Rats subjected to 2 hour of MCA occlusion followed by 1 hour of reperfusion did not show an increase in permeability in ischemic areas after PBS vehicle infusion (Figure 11). In contrast, rats subjected to similar ischemic conditions followed by intra arterial infusion of activators of K_{Ca} channels, for example bradykinin or NS-1619 (Figure 11) or nitric oxide donors (data not shown), enhanced permeability to the dye. The increased permeability to the dye produced by the potassium channel activators was diminished by co-infusion with the specific K_{Ca} inhibitor IBTX, indicating the specific involvement of K_{Ca} (Figure 11).

IN THE CLAIMS

1. A method of delivering a medicant to an abnormal brain region in a mammalian subject, comprising:

5 administering to a mammalian subject having an abnormal brain region a potassium channel agonist, other than bradykinin or a bradykinin analog, under conditions and in an amount sufficient to increase the permeability to the medicant of a capillary or arteriole delivering blood to cells of the abnormal brain region; and

10 administering to the subject simultaneously or substantially simultaneously with the potassium channel agonist the medicant, so that the medicant is delivered selectively to the cells of the abnormal brain region compared to normal brain regions.

2. The method of Claim 1, wherein the abnormal brain region is a region of brain tissue physiologically affected by injury, trauma, infection, stroke, or ischemia.

15 3. The method of Claim 1, wherein the abnormal brain region is a region of benign or malignant tumor tissue.

20 4. The method of Claim 1, wherein the potassium channel agonist is NS-1619, 1-EBIO, a guanylyl cyclase activator, a guanylyl cyclase activating protein, minoxidil, pinacidil, cromakalim, or levcromakalim.

5. The method of Claim 1, wherein said mammal is a human, non-human primate, canine, feline, bovine, porcine, ovine, mouse, rat, gerbil, hamster, or rabbit.

25 6. The method of Claim 1, wherein the medicant is a therapeutic cytotoxic agent, DNA expression vector, viral vector, protein, oligonucleotide, nucleotide analog, antimicrobial agent, interferon, cytokine, cytokine agonist, cytokine antagonist, immunotoxin, immunosuppressant, boron compound, monoclonal antibody, adrenergic agent, anticonvulsant, ischemia-protective agent, anti-trauma agent, anticancer chemotherapeutic agent, or diagnostic agent.

7. The method of Claim 6, wherein the diagnostic agent is an imaging or contrast agent.

8. The method of Claim 6, wherein the diagnostic agent is a radioactively labeled substance, a gallium-labeled substance, or a contrast agent selected from the group consisting of ferrous magnetic, fluorescent, luminescent, and iodinated contrast agents.

5 9. The method of Claim 1, wherein the medicant is a N-methyl-D-aspartate (NMDA) receptor antagonist, antibiotic, interleukin-2; or transforming growth factor- β , cisplatin, carboplatin, tumor necrosis factor- α , methotrexate, 5-fluorouracil, amphotericin, daunorubicin, doxorubicin, vincristine, vinblastine, busulfan, chlorambucil, cyclophosphamide, melphalan, or ethyl ethanesulfonic acid.

10. The method of Claim 6, wherein the viral vector is an adenovirus-derived vector or herpes simplex virus-derived vector.

10 11. The method of Claim 1, wherein administering the potassium channel agonist is by intravenous or intra-arterial infusion or injection.

12. The method of Claim 1, wherein administering the potassium channel agonist is by intracarotid infusion or injection.

15 13. The method of Claim 1, wherein the potassium channel agonist is administered to the mammalian subject by a bolus injection.

14. The method of Claim 1, wherein the potassium channel agonist is administered to the mammalian subject in an amount from about 0.075 to 1500 micrograms per kilogram body mass.

20 15. The method of Claim 14, wherein the potassium channel agonist is administered to the subject in an amount from about 0.075 to 150 micrograms per kilogram body mass.

16. The method of Claim 1, wherein the potassium channel agonist is administered to the mammalian subject at a dose rate of about 0.075 to about 100 $\mu\text{g kg}^{-1} \text{ min}^{-1}$ for up to about 30 minutes.

25 17. The method of Claim 16, wherein the potassium channel agonist is administered to the mammalian subject at a dose rate of about 0.075 to about 15 $\mu\text{g kg}^{-1} \text{ min}^{-1}$.

18. A method of selectively delivering a medicant to an abnormal brain region in a mammalian subject, comprising:

administering to a mammalian subject having an abnormal brain region a potassium channel agonist, other than bradykinin or a bradykinin analog, under conditions and in an amount sufficient to increase potassium flux through a calcium-activated or ATP-sensitive potassium channel in an endothelial cell membrane of a capillary or arteriole delivering blood to cells of the abnormal brain region, whereby the capillary or arteriole is made more permeable to the medicant; and

administering to the subject simultaneously or substantially simultaneously with the potassium channel agonist the medicant, so that the medicant is delivered selectively to the cells of the abnormal brain region compared to normal brain regions.

19. The method of Claim 18, wherein the abnormal brain region is a region of brain tissue physiologically affected by injury, trauma, infection, stroke, or ischemia.

20. The method of Claim 18, wherein the abnormal brain region is a region of benign or malignant tumor tissue.

21. The method of Claim 18, wherein the potassium channel agonist is NS-1619, 1-EBIO, a guanylyl cyclase activator, a guanylyl cyclase activating protein, minoxidil, pinacidil, cromakalim, or levromakalim.

22. The method of Claim 18, wherein said mammal is a human, non-human primate, canine, feline, bovine, porcine, ovine, mouse, rat, gerbil, hamster, or rabbit.

23. The method of Claim 18, wherein the medicant is a therapeutic cytotoxic agent, DNA expression vector, viral vector, protein, oligonucleotide, nucleotide analog, antimicrobial agent, interferon, cytokine, cytokine agonist, cytokine antagonist, immunotoxin, immunosuppressant, boron compound, monoclonal antibody, adrenergic agent, anticonvulsant, ischemia-protective agent, anti-trauma agent, anticancer chemotherapeutic agent, or diagnostic agent.

24. The method of Claim 23, wherein the diagnostic agent is an imaging or contrast agent.

25. The method of Claim 23, wherein the diagnostic agent is a radioactively labeled

substance, a gallium-labeled substance, or a contrast agent selected from the group consisting of ferrous magnetic, fluorescent, luminescent, and iodinated contrast agents.

26. The method of Claim 18, wherein the medicant is a N-methyl-D-aspartate (NMDA) receptor antagonist, antibiotic, interleukin-2; or transforming growth factor- β , cisplatin, carboplatin, tumor necrosis factor- α , methotrexate, 5-fluorouracil, amphotericin, daunorubicin, doxorubicin, vincristine, vinblastine, busulfan, chlorambucil, cyclophosphamide, melphalan, or ethyl ethanesulfonic acid.

27. The method of Claim 23, wherein the viral vector is an adenovirus-derived vector or herpes simplex virus-derived vector.

28. The method of Claim 18, wherein administering the potassium channel agonist is by intravenous or intra-arterial infusion or injection.

29. The method of Claim 18, wherein administering the potassium channel agonist is by intracarotid infusion or injection.

30. The method of Claim 18, wherein the potassium channel agonist is administered to the mammalian subject by a bolus injection.

31. The method of Claim 18, wherein the potassium channel agonist is administered to the mammalian subject in an amount from about 0.075 to 1500 micrograms per kilogram body mass.

32. The method of Claim 31, wherein the potassium channel agonist is administered to the subject in an amount from about 0.075 to 150 micrograms per kilogram body mass.

33. The method of Claim 18, wherein the potassium channel agonist is administered to the mammalian subject at a dose rate of about 0.075 to about 100 $\mu\text{g kg}^{-1} \text{ min}^{-1}$ for up to about 30 minutes.

34. The method of Claim 33, wherein the potassium channel agonist is administered to the mammalian subject at a dose rate of about 0.075 to about 15 $\mu\text{g kg}^{-1} \text{ min}^{-1}$.

35. A method of delivering a medicant to a malignant tumor in a mammalian subject,

comprising:

administering to a mammalian subject having a malignant tumor a potassium channel agonist, other than bradykinin or a bradykinin analog, under conditions and in an amount sufficient to increase the permeability to the medicant of a capillary or arteriole delivering blood to cells of the malignant tumor; and

5 administering to the subject simultaneously or substantially simultaneously with the potassium channel agonist the medicant, so that the medicant is delivered selectively to the malignant cells compared to non-malignant cells.

10 36. The method of Claim 35, wherein the potassium channel agonist is NS-1619, 1-EBIO, a guanylyl cyclase activator, a guanylyl cyclase activating protein, minoxidil, pinacidil, cromakalim, or levocromakalim.

37. The method of Claim 35, wherein the malignant tumor is a glioma, glioblastoma, oligodendroglioma, astrocytoma, ependymoma, primitive neuroectodermal tumor, atypical meningioma, malignant meningioma, neuroblastoma, sarcoma, melanoma, lymphoma, or carcinoma.

15 38. The method of Claim 35, wherein the malignant tumor is contained in the skull, brain, spine, thorax, lung, peritoneum, prostate, ovary, uterus, breast, stomach, liver, bowel, colon, rectum, bone, lymphatic system, or skin, of said subject.

39. The method of Claim 35, wherein said mammal is a human, non-human primate, canine, feline, bovine, porcine, ovine, mouse, rat, gerbil, hamster, or rabbit.

20 40. The method of Claim 35, wherein the medicant is a therapeutic cytotoxic agent, DNA expression vector, viral vector, protein, oligonucleotide, nucleotide analog, antimicrobial agent, interferon, cytokine, cytokine agonist, cytokine antagonist, immunotoxin, immunosuppressant, boron compound, monoclonal antibody, adrenergic agent, anticonvulsant, ischemia-protective agent, anti-trauma agent, anticancer chemotherapeutic agent, or diagnostic agent.

25 41. The method of Claim 40, wherein the diagnostic agent is an imaging or contrast agent.

42. The method of Claim 40, wherein the diagnostic agent is a radioactively labeled

substance, a gallium-labeled substance, or a contrast agent selected from the group consisting of ferrous magnetic, fluorescent, luminescent, and iodinated contrast agents.

43. The method of Claim 35, wherein the medicant is a N-methyl-D-aspartate (NMDA) receptor antagonist, antibiotic, interleukin-2; or transforming growth factor- β , cisplatin, carboplatin, tumor necrosis factor- α , methotrexate, 5-fluorouracil, amphotericin, daunorubicin, doxorubicin, vincristine, vinblastine, busulfan, chlorambucil, cyclophosphamide, melphalan, or ethyl ethanesulfonic acid.

44. The method of Claim 40, wherein the viral vector is an adenovirus-derived vector or herpes simplex virus-derived vector.

45. The method of Claim 35, wherein administering the potassium channel agonist is by intravenous or intra-arterial infusion or injection.

46. The method of Claim 35, wherein the tumor is an intracranial tumor and the potassium channel agonist is administered by intracarotid infusion or injection.

47. The method of Claim 35, wherein the potassium channel agonist is administered to the mammalian subject by a bolus injection.

48. The method of Claim 35, wherein the potassium channel agonist is administered to the mammalian subject in an amount from about 0.075 to 1500 micrograms per kilogram body mass.

49. The method of Claim 48, wherein the potassium channel agonist is administered to the mammalian subject in an amount from about 0.075 to 150 micrograms per kilogram body mass.

50. The method of Claim 35, wherein the potassium channel agonist is administered to the mammalian subject at a dose rate of about 0.075 to about $100 \mu\text{g kg}^{-1} \text{ min}^{-1}$ for up to about 30 minutes.

51. The method of Claim 50, wherein the potassium channel agonist is administered to the mammalian subject at a dose rate of about 0.075 to about $15 \mu\text{g kg}^{-1} \text{ min}^{-1}$.

52. A method of delivering a medicant to a malignant tumor in a mammalian subject,

comprising:

administering to the mammalian subject having a malignant tumor a potassium channel agonist, other than bradykinin or a bradykinin analog, under conditions and in an amount sufficient to increase potassium flux through a calcium-activated or ATP-sensitive potassium channel in an endothelial cell membrane of a capillary or arteriole delivering blood to malignant cells of the tumor, whereby the capillary or arteriole is made more permeable to the medicant; and

administering to the subject simultaneously or substantially simultaneously with the potassium channel agonist the medicant, so that the medicant is delivered selectively to the malignant cells compared to non-malignant cells.

53. The method of Claim 52, wherein the potassium channel agonist is NS-1619, 1-EBIO, a guanylyl cyclase activator, a guanylyl cyclase activating protein, minoxidil, pinacidil, cromakalim, or levromakalim.

54. The method of Claim 52, wherein the malignant tumor is a glioma, glioblastoma, oligodendroglioma, astrocytoma, ependymoma, primitive neuroectodermal tumor, atypical meningioma, malignant meningioma, neuroblastoma, sarcoma, melanoma, lymphoma, or carcinoma.

55. The method of Claim 52, wherein the malignant tumor is contained in the skull, brain, spine, thorax, lung, peritoneum, prostate, ovary, uterus, breast, stomach, liver, bowel, colon, rectum, bone, lymphatic system, or skin, of said subject.

56. The method of Claim 52, wherein said mammal is a human, non-human primate, canine, feline, bovine, porcine, ovine, mouse, rat, gerbil, hamster, or rabbit.

57. The method of Claim 52, wherein the medicant is a therapeutic cytotoxic agent, DNA expression vector, viral vector, protein, oligonucleotide, nucleotide analog, antimicrobial agent, interferon, cytokine, cytokine agonist, cytokine antagonist, immunotoxin, immunosuppressant, boron compound, monoclonal antibody, adrenergic agent, anticonvulsant, ischemia-protective agent, anti-trauma agent, anticancer chemotherapeutic agent, or diagnostic agent.

58. The method of Claim 57, wherein the diagnostic agent is an imaging or contrast agent.

59. The method of Claim 57, wherein the diagnostic agent is a radioactively labeled substance, a gallium-labeled substance, or a contrast agent selected from the group consisting of ferrous magnetic, fluorescent, luminescent, and iodinated contrast agents.

5 60. The method of Claim 52, wherein the medicant is a N-methyl-D-aspartate (NMDA) receptor antagonist, antibiotic, interleukin-2; or transforming growth factor- β , cisplatin, carboplatin, tumor necrosis factor- α , methotrexate, 5-fluorouracil, amphotericin, daunorubicin, doxorubicin, vincristine, vinblastine, busulfan, chlorambucil, cyclophosphamide, melphalan, or ethyl ethanesulfonic acid.

61. The method of Claim 57, wherein the viral vector is an adenovirus-derived vector or herpes simplex virus-derived vector.

10 62. The method of Claim 52, wherein administering the potassium channel agonist is by intravenous or intra-arterial infusion or injection.

63. The method of Claim 52, wherein the tumor is an intracranial tumor and the potassium channel agonist is administered by intracarotid infusion or injection.

15 64. The method of Claim 52, wherein the potassium channel agonist is administered to the mammalian subject by a bolus injection.

65. The method of Claim 52, wherein the potassium channel agonist is administered to the mammalian subject in an amount from about 0.075 to 1500 micrograms per kilogram body mass.

20 66. The method of Claim 65, wherein the potassium channel agonist is administered to the mammalian subject in an amount from about 0.075 to 150 micrograms per kilogram body mass.

67. The method of Claim 52, wherein the potassium channel agonist is administered to the mammalian subject at a dose rate of about 0.075 to about 100 $\mu\text{g kg}^{-1} \text{ min}^{-1}$ for up to about 30 minutes.

25 68. The method of Claim 67, wherein the potassium channel agonist is administered to the mammalian subject at a dose rate of about 0.075 to about 15 $\mu\text{g kg}^{-1} \text{ min}^{-1}$.

69. A method of treating a malignant tumor in a human subject, comprising:

administering to a human subject having a malignant tumor a potassium channel agonist, other than bradykinin or a bradykinin analog, under conditions and in an amount sufficient to increase the permeability to the medicant of a capillary or arteriole delivering blood to cells of the malignant tumor; and

5 administering to the subject simultaneously or substantially simultaneously with the potassium channel agonist the medicant, so that the medicant is delivered selectively to the malignant cells compared to non-malignant cells.

70. The method of Claim 69, wherein the potassium channel agonist is NS-1619, 1-EBIO, a guanylyl cyclase activator, a guanylyl cyclase activating protein, minoxidil, pinacidil, cromakalim, or
10 levromakalim.

71. The method of Claim 69, wherein the malignant tumor is a glioma, glioblastoma, oligodendroglioma, astrocytoma, ependymoma, primitive neuroectodermal tumor, atypical meningioma, malignant meningioma, neuroblastoma, sarcoma, melanoma, lymphoma, or carcinoma.

72. The method of Claim 69, wherein the malignant tumor is contained in the skull, brain,
15 spine, thorax, lung, peritoneum, prostate, ovary, uterus, breast, stomach, liver, bowel, colon, rectum, bone, lymphatic system, or skin, of said subject.

73. The method of Claim 69, wherein the medicant is a therapeutic cytotoxic agent, DNA expression vector, viral vector, protein, oligonucleotide, nucleotide analog, antimicrobial agent, interferon,
20 cytokine, cytokine agonist, cytokine antagonist, immunotoxin, immunosuppressant, boron compound, monoclonal antibody, adrenergic agent, anticonvulsant, ischemia-protective agent, anti-trauma agent, anticancer chemotherapeutic agent, or diagnostic agent.

74. The method of Claim 73, wherein the diagnostic agent is an imaging or contrast agent.

75. The method of Claim 73, wherein the diagnostic agent is a radioactively labeled
25 substance, a gallium-labeled substance, or a contrast agent selected from the group consisting of ferrous magnetic, fluorescent, luminescent, and iodinated contrast agents.

76. The method of Claim 69, wherein the medicant is a N-methyl-D-aspartate (NMDA)

receptor antagonist, antibiotic, interleukin-2; or transforming growth factor- β , cisplatin, carboplatin, tumor necrosis factor- α , methotrexate, 5-fluorouracil, amphotericin, daunorubicin, doxorubicin, vincristine, vinblastine, busulfan, chlorambucil, cyclophosphamide, melphalan, or ethyl ethanesulfonic acid.

5 77. The method of Claim 73, wherein the viral vector is an adenovirus-derived vector or herpes simplex virus-derived vector.

78. The method of Claim 69, wherein administering the potassium channel agonist is by intravenous or intra-arterial infusion or injection.

10 79. The method of Claim 69, wherein the tumor is an intracranial tumor and the potassium channel agonist is administered by intracarotid infusion.

80. The method of Claim 69, wherein the potassium channel agonist is administered to the mammalian subject by a bolus injection.

15 81. The method of Claim 69, wherein the potassium channel agonist is administered to the subject in an amount from about 0.075 to 150 micrograms per kilogram body mass.

82. The method of Claim 69, wherein the potassium channel agonist is administered to the subject at a dose rate of about 0.075 to about 15 $\mu\text{g kg}^{-1} \text{ min}^{-1}$.

20 83. A method of treating a malignant tumor in a human subject, comprising:
administering to a human subject, having a malignant tumor, a potassium channel agonist, other than bradykinin or a bradykinin analog, under conditions and in an amount sufficient to increase potassium flux through a calcium-activated or ATP-sensitive potassium channel in an endothelial cell membrane of a capillary or arteriole delivering blood to malignant cells of the malignant tumor, whereby the capillary or arteriole is made more permeable to the medicant; and

25 administering to the subject simultaneously or substantially simultaneously with the potassium channel agonist the medicant, so that the medicant is delivered selectively to the malignant cells compared to non-malignant cells.

84. The method of Claim 83, wherein the potassium channel agonist is NS-1619, 1-EBIO, a guanylyl cyclase activator, a guanylyl cyclase activating protein, minoxidil, pinacidil, cromakalim, or levcromakalim.

85. The method of Claim 83, wherein the malignant tumor is a glioma, glioblastoma, oligodendroglioma, astrocytoma, ependymoma, primitive neuroectodermal tumor, atypical meningioma, malignant meningioma, neuroblastoma, sarcoma, melanoma, lymphoma, or carcinoma.

5 86. The method of Claim 83, wherein the malignant tumor is contained in the skull, brain, spine, thorax, lung, peritoneum, prostate, ovary, uterus, breast, stomach, liver, bowel, colon, rectum, bone, lymphatic system, or skin, of said subject.

10 87. The method of Claim 83, wherein the medicant is a therapeutic cytotoxic agent, DNA expression vector, viral vector, protein, oligonucleotide, nucleotide analog, antimicrobial agent, interferon, cytokine, cytokine agonist, cytokine antagonist, immunotoxin, immunosuppressant, boron compound, monoclonal antibody, adrenergic agent, anticonvulsant, ischemia-protective agent, anti-trauma agent, anticancer chemotherapeutic agent, or diagnostic agent.

88. The method of Claim 87, wherein the diagnostic agent is an imaging or contrast agent.

15 89. The method of Claim 87, wherein the diagnostic agent is a radioactively labeled substance, a gallium-labeled substance, or a contrast agent selected from the group consisting of ferrous magnetic, fluorescent, luminescent, and iodinated contrast agents.

20 90. The method of Claim 83, wherein the medicant is a N-methyl-D-aspartate (NMDA) receptor antagonist, antibiotic, interleukin-2; or transforming growth factor- β , cisplatin, carboplatin, tumor necrosis factor- α , methotrexate, 5-fluorouracil, amphotericin, daunorubicin, doxorubicin, vincristine, vinblastine, busulfan, chlorambucil, cyclophosphamide, melphalan, or ethyl ethanesulfonic acid.

91. The method of Claim 87, wherein the viral vector is an adenovirus-derived vector or herpes simplex virus-derived vector.

25 92. The method of Claim 83, wherein administering the potassium channel agonist is by intravenous or intra-arterial injection.

93. The method of Claim 83, wherein the tumor is an intracranial tumor and the potassium channel agonist is administered by intracarotid infusion.

94. The method of Claim 83, wherein the potassium channel agonist is administered to the

mammalian subject by a bolus injection.

95. The method of Claim 83, wherein the potassium channel agonist is administered to the subject in an amount from about 0.075 to 150 micrograms per kilogram body mass.

96. The method of Claim 83, wherein the potassium channel agonist is administered to the mammalian subject at a dose rate of about 0.075 to about 15 $\mu\text{g kg}^{-1} \text{ min}^{-1}$.

97. A pharmaceutical composition comprising a combination of a potassium channel agonist, other than bradykinin or a bradykinin analog, formulated in a pharmaceutically acceptable solution together with a medicant for delivery by intravascular infusion or injection into a mammal.

98. The pharmaceutical composition of Claim 97, wherein the solution is formulated to deliver a dose rate of about 0.075 to 1500 micrograms per kilogram body mass in a pharmaceutically acceptable fluid volume over a maximum of about thirty minutes.

99. The pharmaceutical composition of Claim 97, wherein the solution is formulated to deliver a dose rate of about 0.075 to 150 micrograms per kilogram body mass in a pharmaceutically acceptable fluid volume over a period of up to thirty minutes.

100. The pharmaceutical composition of Claim 97, wherein the potassium channel agonist is NS-1619, 1-EBIO, a guanylyl cyclase activator, a guanylyl cyclase activating protein, minoxidil, pinacidil, cromakalim, or levromakalim.

101. The pharmaceutical composition of Claim 97, wherein the medicant is a therapeutic cytotoxic agent, DNA expression vector, viral vector, protein, oligonucleotide, nucleotide analog, antimicrobial agent, interferon, cytokine, cytokine agonist, cytokine antagonist, immunotoxin, immunosuppressant, boron compound, monoclonal antibody, adrenergic agent, anticonvulsant, ischemia-protective agent, anti-trauma agent, anticancer chemotherapeutic agent, or diagnostic agent.

102. The pharmaceutical composition of Claim 101, wherein the diagnostic agent is an imaging or contrast agent.

103. The pharmaceutical composition of Claim 101, wherein the diagnostic agent is a

radioactively labeled substance, a gallium-labeled substance, or a contrast agent selected from the group consisting of ferrous magnetic, fluorescent, luminescent, and iodinated contrast agents.

5 104. The pharmaceutical composition of Claim 97, wherein the medicant is a N-methyl-D-aspartate (NMDA) receptor antagonist, antibiotic, interleukin-2; or transforming growth factor- β , cisplatin, carboplatin, tumor necrosis factor- α , methotrexate, 5-fluorouracil, amphotericin, daunorubicin, doxorubicin, vincristine, vinblastine, busulfan, chlorambucil, cyclophosphamide, melphalan, or ethyl ethanesulfonic acid.

 105. The pharmaceutical composition of Claim 101, wherein the viral vector is an adenovirus-derived vector or herpes simplex virus-derived vector.

10 106. The pharmaceutical composition of Claim 97, further comprising a buffer solution pharmaceutically acceptable for intravascular infusion into a mammal.

 107. The pharmaceutical composition of Claim 106, wherein the buffer solution is phosphate buffered saline.

15 108. A kit for enhancing the delivery of a medicant to an abnormal brain region and/or to a malignant tumor, comprising:
 a potassium channel agonist, other than bradykinin or a bradykinin analog; and
 instructions for using the potassium channel agonist for enhancing the delivery of a medicant to an abnormal brain region or to a malignant tumor.

20 109. The kit of Claim 108, wherein the potassium channel agonist is NS-1619, 1-EBIO, a guanylyl cyclase activator, a guanylyl cyclase activating protein, minoxidil, pinacidil, cromakalim, or levromakalim.




Figure 1




Figure 3

Figure 4A



PBS

Original magnification: X 54,000

Figure 4B



Bradykinin

Original magnification: X 87,000

Figure 4C



NSI619

Original magnification: X 87,000

Figure 5



X 8,700

L

Figure 5C



X 21,000

L

Figure 5D



Treated (BK-infusion)


Control (PBS-infusion)

Figure 5A

Figure 5B

Figure 6A


X 8,700



Control (PBS-infusion)

Figure 6B

X 10,800



Treated (BK-infusion)

Figure 6C

X 21,000



Treated (BK-infusion)

Figure 6

6 / 13




Figure 7




Figure 8

7 / 13




Figure 9

Figure 10A




Figure 10B




Figure 10



Figure 2A



Figure 2B




Figure 11



*Figure 12A**Figure 12B*

Figure 13





Figure 14






Figure 15A





Figure 15B

Normal Brain

Periphery

Tumor Center



RG2

RG2

RG2

C6

Figure 16A

Figure 16B

Figure 16C

Figure 16D

Figure 16

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
2 August 2001 (02.08.2001)

PCT

(10) International Publication Number
WO 01/54771 A3

(51) International Patent Classification⁷: **A61K 31/00**,
31/44, 31/40, A61P 35/00

(21) International Application Number: PCT/US01/02743

(22) International Filing Date: 26 January 2001 (26.01.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/491,500 26 January 2000 (26.01.2000) US
09/615,854 14 July 2000 (14.07.2000) US

(71) Applicant: **CEDARS-SINAI MEDICAL CENTER**
[US/US]: 8700 Beverly Boulevard, Los Angeles, CA
90048-1865 (US).

(72) Inventors: **BLACK, Keith, L.**; 1233 Roberto Lane, Los
Angeles, CA 90077 (US). **NINGARAJ, Nagendra, S.**;
6024 Buckingham Parkway #5, Culver City, CA 90230
(US).

(74) Agents: **STEINBERG, Nisan, A.** et al.; Sidley Austin
Brown & Wood, 555 West Fifth Street, Los Angeles, CA
90013-1010 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
20 June 2002

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



WO 01/54771 A3

(54) Title: METHOD FOR USING POTASSIUM CHANNEL AGONISTS FOR DELIVERING A MEDICANT TO AN ABNOR-
MAL BRAIN REGION AND/OR A MALIGNANT TUMOR

(57) Abstract: Disclosed are methods of selectively delivering a medicant to an abnormal brain region and/or to a malignant tumor in a mammalian subject, including a human. A medicant is administered simultaneously or substantially simultaneously with a calcium- or ATP-dependent potassium channel [K_{Ca} or K_{ATP}] activator (other than bradykinin or a bradykinin analog), such as a direct potassium channel agonist or an indirect potassium channel activator, such as an activator of soluble guanylyl cyclase (e.g., nitric oxide or a nitric oxide donor) or an activator of cyclic GMP-dependent protein kinase, whereby the medicant is delivered selectively to the cells of the abnormal brain region and/or to the tumor, compared to normal tissues. Thus, among the disclosures is a method of treating a malignant tumor in a human subject. Also disclosed are pharmaceutical compositions that combine a potassium channel activator together with a medicant and a kit for enhancing the delivery of a medicant to an abnormal brain region and/or to a malignant tumor.

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/US 01/02743

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/00 A61K31/44 A61K31/40 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, EMBASE, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 00 23102 A (NEW YORK UNIVERSITY) 27 April 2000 (2000-04-27) claims 1,4,6-15 page 16, line 9 - line 17 page 16, line 30 - line 35 page 25, line 33 -page 26, line 22	1-13, 18-30, 35-47, 52-64, 69-80, 83-94, 97, 100-109
X	WO 97 31654 A (NICOX S.A.) 4 September 1997 (1997-09-04) page 2, line 3 - line 12 page 3, line 5 -page 7, line 16 tables 1-7	97-109
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *8* document member of the same patent family

Date of the actual completion of the international search

15 April 2002

Date of mailing of the international search report

26/04/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Siatou, E

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/02743

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	OAK Z. CHI ET AL: "Effects of Cyclic GMP on Microvascular Permeability of the Cerebral Cortex" MICROVASCULAR RESEARCH, vol. 58, 1999, pages 35-40, XP002195899 abstract	1-109
Y	WO 91 16355 A (ALKERMES INC.) 31 October 1991 (1991-10-31) claims 1-23 & US 5 112 596 A 12 May 1992 (1992-05-12) cited in the application	1-109
X	EP 0 575 749 A (E.R. SQUIBB & SONS INC.) 29 December 1993 (1993-12-29) claims 1-18	97-109
X	EP 0 555 681 A (E.R. SQUIBB & SONS INC.) 18 August 1993 (1993-08-18) claims 1-13	97-109
A	EP 0 351 767 A (E.R. SQUIBB & SONS INC.) 24 January 1990 (1990-01-24) page 3, line 4 - line 22 page 2, line 17 - line 24 claims 1-7	1-109
A	R. T. BARTUS ET AL: "Controlled Modulation of BBB Permeability Using the Bradykinin Agonist, RMP-7" EXPERIMENTAL NEUROLOGY, vol. 142, 1996, pages 14-28, XP002195901 abstract page 17, left-hand column, line 16 - line 25 page 24, left-hand column, last paragraph -page 25, left-hand column, line 7	1-109
A	W. G. MAYHAN : "Role of nitric oxide in histamine-induced increases in permeability of the blood-brain barrier" BRAIN RESEARCH, vol. 743, 1996, pages 70-76, XP002195900 abstract	1-109

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1, 18, 35, 52, 69, 83, 97 and 108 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds disclosed in claim 4 of the present invention.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 01/02743

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0023102	A	27-04-2000	EP 1135157 A1 WO 0023102 A1	26-09-2001 27-04-2000
WO 9731654	A	04-09-1997	IT MI960352 A1 AU 706591 B2 AU 2092497 A BR 9707739 A CA 2247848 A1 WO 9731654 A1 EP 0904110 A1 HU 9900993 A2 JP 2000506133 T	26-08-1997 17-06-1999 16-09-1997 27-07-1999 04-09-1997 04-09-1997 31-03-1999 28-09-1999 23-05-2000
WO 9116355	A	31-10-1991	US 5112596 A AT 194289 T AU 650020 B2 AU 7860691 A CA 2081308 A1 DE 69132288 D1 DE 69132288 T2 DK 528891 T3 EP 0528891 A1 ES 2147722 T3 GR 3034351 T3 WO 9116355 A1 US 5506206 A US 5268164 A	12-05-1992 15-07-2000 09-06-1994 11-11-1991 24-10-1991 10-08-2000 14-12-2000 09-10-2000 03-03-1993 01-10-2000 29-12-2000 31-10-1991 09-04-1996 07-12-1993
EP 575749	A	29-12-1993	US 5262419 A AU 665086 B2 AU 4016793 A CA 2096266 A1 EP 0575749 A2 HU 65097 A2 JP 6056698 A MX 9303421 A1 NO 932121 A ZA 9303959 A	16-11-1993 14-12-1995 16-12-1993 12-12-1993 29-12-1993 28-04-1994 01-03-1994 29-07-1994 13-12-1993 05-01-1994
EP 555681	A	18-08-1993	CA 2088455 A1 EP 0555681 A1 JP 5255087 A	14-08-1993 18-08-1993 05-10-1993
EP 351767	A	24-01-1990	CA 1336963 A1 EP 0351767 A2 JP 2048527 A US 5256688 A US 5354764 A	12-09-1995 24-01-1990 19-02-1990 26-10-1993 11-10-1994